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Abstract
In 1871, the observation of yellowish nodules in the enlarged spleen of a cow was considered to
be the first reported case of bovine leukemia. The etiological agent of this lymphoproliferative
disease, bovine leukemia virus (BLV), belongs to the deltaretrovirus genus which also includes the
related human T-lymphotropic virus type 1 (HTLV-1). This review summarizes current knowledge
of this viral system, which is important as a model for leukemogenesis. Recently, the BLV model
has also cast light onto novel prospects for therapies of HTLV induced diseases, for which no
satisfactory treatment exists so far.
1. Background
The occurrence in cattle of a disease called "leukosis" was
first reported by Leisering who described as early as in
1871 the presence of yellowish nodules in the enlarged
spleen of a cow [1]. In fact, spleen disruption consecutive
to tumor formation is one of the most spectacular clinical
manifestations of bovine leukemia. These tumors which
result from a local accumulation of transformed B cells
also infiltrate other tissues such as liver, heart, eye, skin,
lung and lymph nodes (reviewed in [2-5]). Two types of
bovine leukemia can be dissociated on the basis of their
epidemiology: Enzootic Bovine Leukosis (EBL), a disease
caused by a retrovirus called BLV (Bovine Leukemia
Virus), and sporadic bovine leukosis which is not trans-
missible. Besides the lethal form of BLV-induced leuke-
mia, persistent lymphocytosis (PL) is characterized by a
permanent and relatively stable increase in the number of
B lymphocytes in the peripheral blood. The PL stage,
which affects approximately one third of infected animals,
is considered to be a benign form of the disease resulting
from the accumulation of untransformed B lymphocytes.
Finally, viral infection is asymptomatic in the majority of
BLV-infected animals; in these settings, fewer than 1 % of
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peripheral blood cells in animals are found to be infected
by virus.
BLV is transmitted horizontally through the transfer of
infected cells via direct contact, through milk and possibly
by insect bites [6]. However, iatrogenic procedures like
dehorning, ear tattooing and, any use of infected needles
contribute significantly to viral spread [7-10]. BLV is now-
adays highly prevalent in several regions of the world (e.g.
United States) and induces major economical losses in
cattle production and export [11-21]. For instance, the
loss to the dairy industry due to BLV in 2003 was esti-
mated annually at $525 million. In contrast, Denmark
was the first country where the virus has been eradicated
through the systematic destruction of infected herds. It is
remarkable that the identification of infected animals was
performed on basis of peripheral blood cell counts with-
out the availability of specific serological tests (Bendixen's
key) [22]. BLV is now almost completely eradicated from
the European Union after many years of culling infected
animals. Since these costly eradication programs are only
possible in regions where viral prevalence is low, other
strategies have also been considered including isolation of
infected animals, passive immunization with colostrum,
vaccination with viral proteins or attenuated strains, as
well as some other exotic approaches ([5,23-34] and ref-
erences therein). None of these latter methods currently
achieve the optimal combination of efficiency, economy
and safety.
Domestic cattle are the natural hosts for BLV. The exist-
ence of wild reservoirs remains controversial, but convinc-
ing evidence indicates that BLV indeed persists in water
buffaloes [35-37]. Experimental transmissions of BLV
have been reported in many species including rabbits [38-
40], rats [41,42], chickens [43], pigs [44], goats [45] and
sheep [9,46-48]. However, only sheep consistently
develop leukemia whereas rabbits present immune dys-
functions (but no tumors, in a finding different from rab-
bits inoculated with HTLV [49]). Rare cases of
experimental transformation were reported in goats, rats
and even chicken. Despite successful infection of a series
of cell lines in vitro [50-53], BLV does not persistently
infects cat, dog, monkey or human although viral-specific
seroconversion might occur in these species. Epidemio-
logical studies have shown that consumption of raw milk
from BLV-infected cattle does not increase the frequency
of leukemia in man (reviewed in [54-56]). Therefore, it is
unlikely that BLV infects, replicates and induces cancer in
humans, although this cannot be formally excluded [57].
Instead, four BLV related retroviruses have been isolated
in man: Human T-lymphotropic viruses type 1 to 4
(HTLV-1 to -4) [58-60]. Among these, HTLV-1 infects
about 20 million people worldwide, a fraction of whom
(about 2–3 %) progress to develop acute T-cell leukemia
(ATL) or HTLV-Associated Myelopathy/Tropical Spastic
Paraparesis (HAM/TSP), a neuroinflammatory disease of
the central nervous system.
2. The BLV genome
In addition to the structural gag,  pol  and  env  genes
required for the synthesis of the viral particle, the BLV
genome contains a X region located between the envelope
and the 3' long terminal repeat [61-63], as also observed
in other deltaretroviruses [58,60]. Phylogenetic compari-
sons of different strains, using the pol gene as a reference,
indicate that BLV and primate T-lymphotropic viruses
(PTLV) sequences differ by 42 % [64]; thus BLV forms a
distinct clade amongst retroviruses. Within the BLV sub-
group, the sequence divergence was below 6% in pol and
env indicating a high degree of conservation among differ-
ent geographical strains [24,25,65-67]. Although the rea-
sons are unknown, this genomic stability might result
from a higher fidelity of reverse transcription or from strict
replication constraints.
The genomic RNA
Morphologically, the viral particle with a diameter rang-
ing between 60 and 125 nm, is constituted by a central
electron dense nucleoid surrounded by an outer viral
envelope [68,69] (Figure 1). Infectious virions contain
60–70 S ribonucleic acids resulting from the association
of two 38 S poly-A containing RNA molecules [70].
Transcription of the genomic RNA initiates at the U3/R
boundary of the 5' LTR (long terminal repeat) and termi-
nates at the polyadenylation site (Figure 2). This genomic
RNA interacts with matrix (MA) p15 and nucleocapsid
(NC) p12 proteins and dimerizes through a region sur-
rounding the primer binding site [71,72]. Efficient encap-
sidation of the RNA requires two regions: a primary signal
which is located in the untranslated leader region between
the primer binding site and near the gag start codon and a
second fragment within the 5' end of the gag gene [73].
Both regions fold into secondary structures that are
required for efficient packaging [74-76]. The primary
encapsidation signal does not overlap with a structure
important for cell-free dimer formation but fits with a
region interacting with MA. Replacement of the BLV RNA
region containing the primary and secondary encapsida-
tion signals with a similar region from HTLV-1 or -2 yields
a recombinant virus competent for replication in cell cul-
ture. Heterologous RNAs can be packaged into BLV parti-
cles by means of a minimal RNA packaging sequence [77].
Viral RNA packaging requires the involvement of both the
MA and NC domains of Pr145gag-pol, in particular con-
served basic residues of MA as well as residues of the zinc
finger domains of NC [78].Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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The 3' end of the genomic RNA also contains a highly
structured region (RxRE), which is needed to mediate
RNA transport from the nucleus to the cytoplasm (see par-
agraph on post-transcriptional regulation by Rex). After
transcription and nuclear export, the genomic RNA can
either be directly translated to yield the Pr145gag-pol precur-
sor or incorporated into a budding viral particle.
The long terminal repeat
The genomic RNA is a 9 kb ribonucleic acid molecule
flanked by R regions of the long terminal repeats (Figure
2). In addition to this transcript, a series of other RNAs can
be synthesized in infected cells with two major species of
5.1 kb (the env RNA) and 2.1 kb (tax/rex) and several less
abundant RNAs coding for R3 and G4 [79,80]. All these
transcripts initiate at the boundary between U3 and R (the
CAP site) and terminate with polyadelylation at the end of
R in the 3' LTR. The U3 region contains the canonical pro-
moter "CAT" box (CCAACT at coordinates -97 to -92) and
"TATA" boxes (GATAAAT between -44 and -38). Another
series of sites mainly located in the U3 region of the 5' LTR
regulate viral transcription [81,82].
A key regulatory element of the LTR is a triplicate copy of
a 21 bp sequence called TxRE harboring in the middle of
the sequence an almost perfectly conserved cyclic-AMP
Schematic representation of the BLV viral particle Figure 1
Schematic representation of the BLV viral particle. Two copies of single stranded genomic RNA are packaged in a viral 
particle. The CA (p24) proteins form a capsid that contains the viral RNA in interaction with nucleocapsid NC (p12). Two 
enzymatic proteins (RT and IN) required, respectively, for reverse transcription and integration of the viral genome are also 
packaged into the capsid. The matrix protein MA (p15) interconnects the capsid and the outer envelope that is formed by a 
lipid bilayer of cellular origin in which a complex of viral proteins (gp51 SU and gp30 TM) are inserted.
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Structure of the BLV provirus: genes, RNA transcripts and viral protein Figure 2
Structure of the BLV provirus: genes, RNA transcripts and viral protein. The provirus is flanked by two identical 
long terminal repeat sequences (LTRs) and contains the open reading frames (orfs) corresponding to gag, prt (protease), pol 
and env. Several orfs coding for Tax, Rex, R3 and G4 are present in the X region between env and the 3'LTR. The genomic 
RNA transcript initiates and terminates in the 5' and 3' LTRs, respectively. This genomic RNA serves as a template for the 
expression of the gag-prt-pol precursors (pr145, pr66 and pr44) that are processed in structure and enzymatic proteins: 
matrix (MA) p15, capsid (CA) p24, nucleocapsid (NC) p12, protease (PRT) p14 and, p80 (RT/IN) harboring reverse tran-
scriptase, RNAse H and integrase activities. A large intron corresponding to gag-prt-pol is excised to yield the envelope (env) 
RNA. After translation, the pr72 precursor is cleaved in two subunits: the extracellular (SU) gp51 and the transmembrane 
(TM) gp30 glycoproteins. To generate the Tax/Rex messenger RNA, a second intron is cleaved. This double-spliced RNA 
encodes both the p34 Tax protein using an initiation codon at the end of pol and Rex which shares the same AUG as Env pr72. 
Two minor RNAs identified by RT/PCR code for p5 (R3) and p11 (G4). The R3 RNA is similar to the double-spliced Tax/Rex 
message but the second intron is shorter and splicing occurs at the 5' end of the R3 frame. The R3 protein shares its aminote-
rminal end with Rex and pr72. In the G4 message, a very large intron is excised between a particular splice donor site different 
from that of the other viral RNAs and an acceptor just 5' to the G4 frame. The G4 protein initiates at a suboptimal CUG 
codon located in R of the 5'LTR.
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responsive element (CRE) with an overlapping E box
motif. Only two of these TxREs are required for infectivity
and pathogenicity in sheep [83]. In gel retardation assays
with primary B lymphocyte lysates, the TxRE element
interacts with the CREB, ATF-1 and ATF-2 transcription
factors and the amount of protein-DNA complex corre-
lates with the level of viral expression [84,85]. The CREB/
ATF transcription factors regulate LTR-directed transcrip-
tion when activated by two cellular protein kinases (i.e.
PKA and CaMKIV). The 21 bp enhancer is also a target of
the Tax protein, a viral transcriptional activator which
increases the binding of CREB to DNA [86]. In fact, the
internal CRE-like sequences (AGACGTCA, TGACG GCA,
TGACCTCA), a property which is shared by the related
HTLV-1 LTR [87], are close to but different from the con-
sensus "TGACGTCA". Restoring a perfect CRE sequence
into the 21 bp sequences increases the BLV LTR promoter
activity in reporter assays, but interferes with viral replica-
tion in vivo [88]. Indeed, the proviral loads are drastically
reduced in sheep infected with a virus harboring perfect
consensus CRE elements (see section 4, below). Another
regulatory process is exerted by E-box motifs which over-
lap the CRE elements and repress basal LTR-driven gene
expression [89].
Although the 21 bp enhancer is a major regulator of viral
expression, other U3 elements also modulate LTR-
directed transcription. Among them, a NF-κB-related site
located between the proximal and middle 21 bp enhanc-
ers, binds in vitro to several members of the kappa B family
of proteins including p49, p50 and p65 and confers fur-
ther transcriptional activation [90,91]. Another motif,
located just 5' to the proximal 21 bp, is required for
responsiveness of the LTR promoter to glucocorticoids
[92,93]. A PUbox located at coordinates -95/-84 bp specif-
ically interacts with PU.1 and the related Ets transcription
factor Spi-B [94]. Mutations within this element decrease
LTR-driven basal gene expression but does not impair
responsiveness to Tax. An E-box motif (5'-CACGTG-3')
located downstream of the transcription start site binds
the basic helix-loop-helix transcription factors USF1 and
USF2 and regulates the LTR promoter [95]. In addition to
these U3 elements, viral expression is regulated also by
sequences in the R region [81]. Finally, an interferon reg-
ulatory factor binding site in U5 interacts with IRF-1 and
IRF-2 and stimulates basal expression in the absence of
Tax [96]. Viral transcription thus appears to be regulated
by numerous sites distributed throughout the 5' LTR.
Viral transcription is regulated at a separate level by epige-
netic modifications such as acetylation of histone mole-
cules and DNA methylation. Indeed, cultivation of
peripheral blood mononuclear cells (PBMCs) from BLV-
infected animals in the presence of histone deacetylase
(HDAC) inhibitors significantly increases viral expression
[97]. A close correlation links the level of histone acetyla-
tion and transcriptional activation of the LTR [89]. HDAC
inhibitors synergistically enhance transactivation of the
LTR by Tax in a CRE-dependent manner [98]. Trichostatin
A increases the occupancy of the CRE elements by CREB/
ATF as shown by chromatin immunoprecipitation assays.
DNA methylation could be another means for regulating
LTR-transcription. Indeed, in vitro methylation of the LTR
by CpG methyltransferase SssI reduces LTR activity in luci-
ferase reporter assays [99]. However, only minimal modi-
fications of CpG methylation were detected at all stages
examined in BLV-infected cattle and sheep. Further exper-
iments are therefore required to clarify the role of methyl-
ation in LTR activity, as has been described in the HTLV
system [100].
Finally, viral expression is also regulated at the post-tran-
scriptional level by a viral protein called Rex which inter-
acts with RNA sequences in the 3'LTR located between the
AATAAA signal and the polyadenylation site [101]. This
region is able to fold into a stable RNA hairpin structure
and brings the two transcription termination signals
together. Rex binding is required for the nuclear to cyto-
plasmic export of unspliced and singly spliced, but not for
multiply spliced, BLV transcripts.
The gag and protease genes
The gag gene codes for the Pr44gag precursor, a polypeptide
subsequently cleaved into the major non-glycosylated
proteins of the viral particle (p15, p24 and p12) (Figure 2)
[70,102-106]. The matrix (MA) protein p15 (109 aa)
which corresponds to the NH2-terminal end of the gag
precursor is a myristylated and phosphorylated polypep-
tide. MA proteins bind the genomic viral RNA but also
interact with the lipid bilayer of the viral membrane.
Structurally, MA contains four principal helices that are
joined by short loops [107]. The matrix protein can be fur-
ther proteolytically processed to generate three fragments:
p10, a seven amino acids product, and p4 [71]. p10,
which is also myristylated, results from the amino-termi-
nal cleavage of MA.
The p12 nucleocapsid (NC) is a proline-rich 69 aa protein
that is tightly bound to the packaged genomic RNA
[71,108]. In the presence of Zn2+, NC interacts with sin-
gle-stranded nucleic acids with an affinity in the nanomo-
lar range [109].
p24, a neutral and moderately hydrophobic protein, is the
major constituent of the capsid (CA) of BLV virions. The
CA protein appears to be a major target for the host
immune response with high antibody titers found in the
sera of infected animals and two defined regions of p24
being recognized by specific T lymphocytes [110,111].Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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One of the T-cell epitopes overlaps with a domain highly
conserved among retroviruses, the major homology
region (MHR), which is required for viral infectivity in vivo
[112]. Based on the use of a monoclonal antibody
directed against BLV p24, a common epitope was found to
be shared with HTLV CA [113,114]. Interestingly, this
cross-reactivity between the capsid antigens of BLV and
HTLV-1 suggests an evolutionary relationship between the
two viruses. Of note, an immunological cross-reaction is
also observed between the BLV and the feline leukemia
virus (FeLV) nucleocapsid NC proteins [115].
Different BLV Gag proteins (MA, CA and NC) are derived
from the proteolytic cleavage of the Pr44gag precursor. This
post-translational maturation is carried out by the viral
protease p14 which is encoded by a region located
between the gag and the pol genes. p14 is synthesized from
a gag-protease precursor (pr66gag-prt) via a frameshift sup-
pression of the gag termination codon by a lysine-specific
tRNA [116]. The pr66gag-prt precursor localizes at the sur-
face of polarized cells [117]. The p14 protein, which
assembles into dimers, belongs to the aspartyl proteinase
group and can be inhibited by pepstatin A [118]. Despite
their evolutionary relationship, the BLV and HTLV pro-
teases harbor marked specificities in cleavage site recogni-
tion [119].
Overexpression of the Gag polyprotein in mammalian
cells generates virus-like particles (VLPs). VLPs production
depends on the PPPY motif located in the MA domain
and on the amino-terminal glycine involved in Gag myri-
stylation. The PPPY sequence functions as a late domain
and plays a role in budding of the viral particle [120,121]
The pol gene
The pol gene is translated via a frameshift mechanism, as a
145-kDa precursor (852 aa) [116]. Pr145 contains all of
the tryptic peptides of the gag-protease precursor and thus
represents an elongation product of pr66gag-prt. The pol
gene encodes a 80 kDa reverse transcriptase (RT), a RNA-
dependent DNA polymerase which is preferentially active
in the presence of Mg2+ [122,123]. In fact, the enzyme
shows a preference for Mg2+ over Mn2+ in both its DNA
polymerase and RNase H activities [124]. BLV RT is rela-
tively resistant to nucleoside triphosphate analogues
known to be potent inhibitors of human immunodefi-
ciency virus (HIV-1) reverse transcriptase. Bacterially pro-
duced BLV RT is enzymatically active as a monomer even
after binding a DNA substrate [125]. Amazingly, sera from
some leukemic cattle contain antibodies that inhibit
reverse transcriptase activity in vitro.
The synthesis of the minus strand DNA by RT begins at the
primer binding site for tRNA pro in the genomic template
RNA located just 2 bp downstream of U5. BLV reverse
transcriptase exhibits a higher fidelity than that from
spleen necrosis virus: only 1.2 × 10-5 base mutations (ver-
sus 4.8 × 10-6 for SNV) occur per round of replication
[126]. In fact, BLV RT shows a fidelity of misinsertion bet-
ter than that of HIV-1 RT but a similar degree of mispair
elongation (i.e. the ability to extend these 3' end mispairs)
[124].
After infection of permissive cells, two species of cova-
lently closed circular DNA molecules, harboring one or
two LTR copies, are synthesized after reverse transcription
[127,128]. Unintegrated viral DNA molecules are abun-
dant in asymptomatic and PL cattle but they appear to be
absent during the tumor phase [129]. Insertion of the
double-stranded DNA, also known as the provirus, is
directed by the virally encoded integrase IN [130,131].
During DNA rearrangement, the integrase recognition
sequence includes the 3' end of the U5 LTR region [131].
Once inserted at random sites into the host genome, the
provirus is flanked by direct repeats of cellular DNA [132].
The envelope gene
The sequences coding for the BLV envelope partially over-
lap in a different frame the 3' end of pol by 51 nucleotides
[62,133,134]. The envelope gene is transcribed as a 5.1 kb
mRNA coding for the pr72env  precursor
[70,80,103,105,106,135]. The BLV and HTLV envelopes
show 36 % of identities in their amino acid sequence. The
BLV pr72env precursor is cleaved into two subunits by sub-
tilisin/kesin-like convertases such as furin [136]. The
resulting products, the extracellular gp51 (SU) and the
transmembrane gp30 (TM) proteins are glycosylated
polypeptides [137-140]. SU and TM associate through
disulfide bonds, conferring a relatively stable complex
[141].
Interestingly, the pr72env  precursor polyprotein is not
evenly distributed but concentrates predominantly in
only one daughter cell [117]. This mechanism might
account for the absence of viral antigens in a proportion
of the cell progeny and permit persistence of the virus (see
hypothetical model in section 6, below)
In contrast to TM which is very poorly immunogenic, the
extracellular SU induces massive expression of specific
antibodies in infected animals, a property useful for diag-
nostics and vaccine development. Some monoclonal anti-
bodies (F, G and H) directed towards conformational
epitopes of SU exhibit neutralizing activities
[137,142,143]. None of the known viral strains are simul-
taneously lacking F, G and H reactivities, suggesting that
loss of these three epitopes probably means loss of infec-
tivity. In addition, rabbit antisera raised against peptides
39–48, 78–92, 144–157 and 177–192 neutralize VSV/
BLV pseudotypes in vitro, indicating that these epitopesRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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are also implicated in viral infectivity [144,145]. Interest-
ingly, residues 144 to 157 of SU correspond to the region
in the HTLV-1 envelope glycoprotein which is also
involved in neutralization. Cell fusion, i.e. syncytium for-
mation, is inhibited by sera directed towards peptides 64–
73, 98–117 and 177–192. This last sequence (in particular
residues P177 and D178 of SU), which stimulates prolif-
eration of lymphocytes isolated from infected cows, is a T-
helper epitope. Finally, CD8-dependent cytotoxic activity
is associated with peptides 121–140, 131–150 [146], or
24–31 [147,148].
In silico modeling indicates that SU glycoprotein oli-
gomerizes as a trimer, in which the putative receptor bind-
ing domain (RBD) corresponds to the most efficient
neutralizing epitopes [141,143,149]. It should be men-
tioned here that this cellular receptor for BLV is still
unknown, in contrast to those of HTLV-1 (i.e. glut-1 and
neuropilin-1) [150,151]. Although a candidate molecule
able to interact with SU has been identified [152], it later
appeared that this protein corresponds to the δ subunit of
adaptor-related protein complex AP3 involved in intracel-
lular vesicle transport [153].
Since cell-free infection by BLV appears to be very ineffi-
cient most probably due to virion instability, the main
route of transmission is thought to occur through fusion
between an infected cell harboring envelope proteins at its
surface and a new target lymphocyte [154,155]. The TM
transmembrane protein is a key factor during this process
which uses a fusion peptide that is able to destabilize the
cell membrane through its oblique insertion into the lipid
bilayer [156] triggered by the dynamic structural reorgan-
ization of the TM aminoterminal end. Two domains of
SU, peptide 19–27 which adopts an amphiphilic structure
[157] and region 39–103 [136], are also required for effi-
cient cell fusion. Finally, a region of SU localized between
residues 104–123 interacts with zinc and affects viral
fusion as well as infectivity in vivo [158].
In addition to its role in cell fusion, the TM protein is
involved in signal transduction via immunoreceptor tyro-
sine-based activation (ITAM) motifs present in the cyto-
plasmic tail [159,160]. The critical site of the ITAMs
consists of a YXXL sequence (where X represents a variable
residue). Similar ITAM motifs are also found in Ig alpha
protein of the B cell antigen receptor complex and can be
recognized by SH2 domains of signaling proteins. When
fused to the CD8 molecule, the TM ITAM motifs are able
to transduce signals through the cell membrane after stim-
ulation with an anti-CD8 antibody. These motifs are also
important for incorporation of envelope proteins into the
virion [161] and are required for infectivity in vivo [162].
Using a similar approach of chimeric proteins, the TM
cytoplasmic domain has been found to be involved in the
modulation of intracellular envelope trafficking [163].
Replacement of two proximal dileucine motifs with
alanines increases the surface display of CD8-TM chimeric
proteins indicating that these motifs downmodulate cell
surface expression of envelope proteins [164].
Besides ITAMs and dileucine motifs, the TM cytoplasmic
tail has homology with immunoreceptor tyrosine-based
inhibition motifs (ITIMs), which are homologous to B-
cell receptor (BCR) and inhibitory co-receptor motifs;
however, the functional relevance of these sites remains
unclear [165]. The TM cytoplasmic tail also contains typi-
cal proline-rich motifs (PXXP) which correspond to SH3
recognition sites. These motifs are not required for viral
infectivity but are important for the maintenance of high
viral load in vivo [166].
Finally, BLV TM interacts with phosphatase SHP-1 that
associates with FcγRIIB and acts as a critical negative regu-
lator of BCR signaling [167]. This association suggests the
hypothesis that TM may act as a decoy to sequester SHP-
1, resulting in up-regulation of BCR signaling.
The R3 and G4 open reading frames
The R3 and G4 open reading frames (orfs) belong to an
intermediate region located between the envelope and the
tax/rex genes. These sequences are transcribed into mRNAs
which are present at very low levels in vivo [79,168]. The
R3 mRNA is bicistronic: the first two exons are common
to the tax/rex messenger but the second intron is shorter
and splicing occurs in the middle of the R3 orf (Figure 2).
The G4 mRNA contains only one intron located between
an unusual splice donor site at position 502 (instead of
305 for the other viral mRNAs) and an acceptor at the 5'
end of G4 (position 7066 according to [62]). In vitro trans-
lation of these mRNAs yield proteins of 5.5 kDa and 11.6
kDa for R3 and G4, respectively. Initiation of G4 transla-
tion occurs at a suboptimal CUG codon in the R region
whereas R3 shares the AUG of both the Rex protein and
the envelope pr72env precursor. R3 thus contains 17 ami-
noterminal residues which are also present in Rex and 27
amino acids from the R3 orf [79]. Since these proteins
share the nucleolus-targeting signal and RNA-binding
motifs, R3 could like Rex, be involved in post-transcrip-
tional regulation of viral expression. R3 is located in the
nucleus and in cellular membranes (Figure 3), as previ-
ously reported for HTLV-1 p12I. In contrast, G4, like p13II,
is localized both in the nucleus and in mitochondria
[169].
G4 is likely implicated in cell transformation because its
ectopic expression in primary rat embryo fibroblasts
induces their immortalization [170]. Furthermore, G4Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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Subcellular localisation of the Tax, Rex, R3 and G4 proteins Figure 3
Subcellular localisation of the Tax, Rex, R3 and G4 proteins. Hela cells were transfected with expression vectors for 
Tax, Rex, R3 and G4, cultivated during 24 hours, indirectly marked with FITC-conjugated antibodies and visualized under a flu-
orescent microscope.
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interacts with farnesyl pyrophosphate synthetase (FPPS),
a protein involved in the mevalonate/squalene pathway
and in synthesis of FPP, a substrate required for prenyla-
tion of Ras [171]. HTLV-1 p13II also specifically interacts
with FPPS and colocalizes with G4 in mitochondria, indi-
cating that both accessory proteins exert related functions.
R3 and G4 are dispensable for infectivity in vivo but the
integrity of these genes is essential to allow efficient prop-
agation inside the host [83,170,172]. Furthermore,
recombinant viruses deleted in R3 and G4 are very poorly
pathogenic in sheep with a single exception out of 20
infected animals having been observed after more than 7
years of latency (Florins et al, manuscript in preparation).
Rex
Almost 3 decades ago, a 18 kDa protein was identified by
in vitro translation of RNA isolated from virions [70]. This
18 kDa product was antigenically unrelated to the viral
structural proteins and originated from the 3' end of the
provirus. Later, it was discovered that this viral protein
resulted from the translation of the rex orf [173,174]. The
rex sequences are well conserved amongst various BLV iso-
lates with less than 5% variation [175].
The Rex protein has a punctate nuclear localization, asso-
ciates with nuclear pores and harbors a nuclear export sig-
nal (Figure 3) [24,25,176]. Rex contains a central leucine-
rich activation domain and amino-terminal arginine-rich
motifs required for RNA-binding and nuclear localiza-
tion.
Rex is required for the accumulation of genomic and sin-
gly-spliced env RNAs [101]. This trans-acting regulation of
viral mRNA processing requires a 250-nucleotide region
located between the AATAAA signal and the polyadenyla-
tion site in the 3'LTR. The Rex proteins of HTLV-1 and BLV
are interchangeable for purposes of post-transcriptional
regulation [177].
The messenger RNA coding for BLV Rex results from the
excision of two introns: one is located between the major
splice site at nucleotide 305 (according to [62]) and an
acceptor at the end of the pol gene (position 4649), and
the other spans residues 4871 to 7247. This complex dou-
ble-splicing mechanism yields a 2.1 kb molecule coding
not only for Rex, but also for the Tax protein [80,178]. In
vitro, the tax/rex message which is not itself regulated by
Rex [101], is present in the cytoplasm during an early
phase preceding the accumulation of the other mRNA
coding for the structural proteins [179]. Finally, the
expression of the tax/rex mRNA but not other viral RNAs,
is maintained in vivo at late phases of leukemia or lym-
phosarcoma [180].
The Tax transactivator
The other protein encoded by the 2.1 kb multiply-spliced
mRNA is Tax, a transcriptional activator of viral expres-
sion. Initiation of tax translation occurs at a methionine
residue located just upstream of the pol  stop codon
[80,181]. The Tax orf is the largest of the X region located
between the env gene and the 3' LTR (Figure 2). The Tax
protein is a target of the host immune response with T and
B epitopes corresponding to regions 110–130/131–150
and 261–280, respectively [182].
The importance of tax has been suggested by the absence
of deletions affecting this orf during the process of leuke-
mogenesis [183,184]. However, some proviruses harbor-
ing deletions in the central portion of the genome do not
contain the second exon required for initiation of Tax.
These deletants are thus unable to express Tax, although
all of them could at least in theory, express G4. It is still
possible that a Tax protein is synthesized via other splicing
processes or is provided in trans by other infected cells
[185]. Besides these speculations, it is clear that the integ-
rity of the tax gene is essential for viral infectivity in vivo
[83,186].
The Tax protein is rich in proline (13 %) and leucine (16
%) residues and has a relatively short half life (5 to 6
hours) [178]. It is mainly localized in the nucleus,
although significant amounts are also present in the
cytosol [187,188] (Figure 3). Tax is post-translationally
modified by phosphorylation of two serine residues (106
and 293) and exhibits at least three forms with measured
isoelectric points of 6.05, 6.25 and 6.45 [188,188,189].
Although its calculated molecular weight is 34,328, Tax
migrates as a 34–38 kDa product, probably due to its
phosphorylation.
The first identified function of Tax is activation of viral
transcription [190,191]. This mechanism of transactiva-
tion by Tax requires interaction with cellular transcription
factors, like CREB, which bind to the 21 bp enhancer ele-
ments in the 5'LTR. A very narrow range of variations is
compatible with full transactivation activity, suggesting
that the present molecular structure of Tax results from
heavy evolutionary constraints [192,193,175]. In addi-
tion to the main phosphorylation sites at serines 106 and
293, Tax is structurally characterized by the presence of an
aminoterminal zinc finger and by a leucine-rich activation
domain located between residues 157 and 197 [188,194].
Deletion of the activation domain or substitutions of
amino acids involved in the zinc finger completely abol-
ish Tax's transactivation activity. The region between
amino acids 245 and 265 of the Tax protein reduces LTR-
directed transactivation [195]. A Tax mutant within this
region, which also harbors increased c-fos transactivation
activity [196], does not propagate virus at higher rates inRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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vivo [197]. PBMCs infected with the Tax mutant virus are
less prone to undergo intrinsic apoptosis ex vivo, a process
which involves the Bcl-xl protein [198].
Besides its function as a transcriptional activator, Tax
induces immortalization of primary rat embryo fibrob-
lasts (REF) [170,194,199]. In addition, Tax cooperates
with the Ha-ras oncogene to induce full transformation of
cells that form tumors when injected into nude mice, a
property shared with G4 (see above). These activities
which are also seen with the Myc oncogene, underline the
immortalizing potential of Tax. Tax is thus not strictly an
oncogene because it does not have a cellular counterpart
but behaves as such in a way similar to the well defined
Myc protein. The oncogenic potential of Tax can be disso-
ciated from its transcriptional activation potential by spe-
cific mutations. Alterations of the zinc finger yield
transactivation-deficient but transformation-competent
mutants [194]. In contrast, the main phosphorylation
sites are dispensable for transactivation but are required
for oncogenicity in the REF system (see section 4)
[200,201].
The mechanisms by which Tax induces transformation are
still largely unknown. Expression of Tax in primary ovine
B lymphocytes, which are dependent on CD154 and inter-
leukin-4, impacts cell proliferation and survival leading to
cytokine independent growth [202]. This immortaliza-
tion process correlates with increased Bcl-2 protein levels,
nuclear accumulation of NFκB and a series of intracellular
pathways which remain to be characterized [203]. Tax
also inhibits base-excision DNA repair of oxidative dam-
age, potentially increasing the accumulation of ambient
mutations in cellular DNA [204].
To further understand its mechanisms of action, Tax-asso-
ciated cellular interacting proteins have been identified
using a two-hybrid approach. For example, Tax directly
binds to tristetraprolin (TTP), a post-transcriptional mod-
ulator of TNFα expression [187]. Tax promotes nuclear
accumulation of TTP and restores TNFα expression by
inhibiting TTP. Interestingly, this process is shared by the
HTLV-1 Tax protein, supporting a key role of this process
during cell transformation. Another Tax-interacting pro-
tein is MSX2, a general repressor of gene expression,
including LTR-dependent transcription [205]. MSX2
repression can be counteracted by overexpression of the
CREB2 and RAP74 transcription factors. A third Tax-bind-
ing protein is the G protein β subunit [206]. In condi-
tional Tax-1-expressing transformed T-lymphocytes, Tax
expression correlates with activation of the SDF-1/CXCR4
pathway.
3. BLV infects B lymphocytes
Although it has been reported that BLV could persist in
other cell types [207-214], it seems clear that the major
target of the virus is a B lymphocyte which expresses sur-
face immunoglobulin M [215-219]. In addition to B lym-
phocytes, BLV also persists in cells of the monocyte/
macrophage lineage. Immunoglobulin γ heavy chains are
frequently found on lymphoma cells from cattle, consist-
ently with a mature B cell phenotype [219,220]. Sequenc-
ing of VDJ rearrangements in IgM-secreting B lymphocytes
from a BLV-infected cow indicates that IgM antibodies are
functional, exhibit polyspecific reactivity and contain
exceptionally long CDR3H [221]. Such long HCDR3s,
which are also often found in poor outcome chronic lym-
phocytic leukemia patients (B-CLL), characterize antibod-
ies directed towards negatively charged autoantigens (e.g.,
DNA) [222].
In addition to these markers pertaining to B lymphocytes,
infected cells frequently co-express the CD5 molecule. B
cell lymphocytosis essentially results from an increased
proliferation of circulating CD5+ B lymphocytes associ-
ated with a lower but significant increase of the CD5- B
cell population [223-226]. Although the provirus has
been detected in both CD5+ and CD5- B lymphocytes
from infected animals, lymphosarcoma cells appear to
exhibit mainly, but not exclusively, the CD5+ B pheno-
type [220]. CD5 physically associates with the BCR in B
lymphocytes from normal but not from PL cattle [227].
BCR crosslinking decreases apoptosis of CD5+ B cells
from uninfected animals but does not impact on those of
PL cattle in which CD5 is already dissociated from the
BCR. In contrast to CD5-negative B cells, BCR in B cells of
PL cattle resists movement into lipid rafts upon stimula-
tion and is only weakly internalized [228]. Disruption of
CD5-BCR interactions and subsequent decreased apopto-
sis in antigenically stimulated B cells may thus be a mech-
anism of BLV-induced PL.
In contrast, the CD5 molecule is often not expressed on
tumor cells from BLV-infected sheep [229,230]. Favored
growth of CD5 positive cells might result from a differ-
ence in susceptibility to apoptosis [231]. Another marker,
the CD11b integrin molecule better defines the leukemic
cell populations, although the virus infects both CD11b+
and CD11b- cells. These two populations also exhibit
marked differences in cell kinetics (see section 6). In addi-
tion, the BLV-target cells express the IL-2 receptor (CD25)
and the major histocompatibility class II complex or a
related molecule previously called the tumor associated
antigen (TAA) [219,220,232-234]. This antigen is proba-
bly the most frequently expressed protein at the surface of
BLV target cells. Monoclonal antibodies recognizing this
molecule inhibit the growth of BLV-infected lymphoid
cells and induce tumor regression. Molecular cloning ofRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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cDNAs corresponding to bovine MHC II (BoLA) indicated
that the TAA is closely related, but not identical to BoLA-
DR. Of note, B lymphocytes from PL cows express
increased spontaneous expression of the MHC class II
molecule [235].
To summarize, it appears that the target cell for BLV is
MHCII+ surface IgM+, CD5+ and CD11b+ with some
fluctuations for the three latter markers at late stages of the
disease. In contrast, HTLV-1 clearly infects other cell types
CD4+ and CD8+ T lymphocytes [236,237], underscoring
a major difference between the two viral systems.
4. Viral genetic determinants required for 
infection and pathogenesis
Although sheep are not natural hosts for BLV, studying
infection and pathogenesis in this model might be
informative for understanding pathogenesis pertaining to
other deltaretroviruses. To circumvent the problem of
genomic RNA instability, infectious proviruses were
cloned and injected into sheep or calves [30,83,238,239].
Hence, infection of sheep with proviral clone 344 leads to
tumor or leukemia after a mean latency period of 33
months [170]. Since the BLV provirus can be re-amplified
from the tumor cells, the three conditions required to ful-
fill Koch's postulate are demonstrated (i.e. the cloning of
the virus, the analysis of its pathogenicity, and its re-isola-
tion from the lesions), clearly establishing viral causality
in leukemia/lymphoma.
Among other isolates, clone 395 is deficient for infectivity
in vivo, due to the presence of a E-to-K mutation at codon
303 of the Tax protein [83,184,186]. In cell culture, trans-
fection of provirus 395 yields reduced levels of Tax activity
(~ 10 % of wild-type) although the amount of major cap-
sid protein p24 expressed inside the cells and in the super-
natant remains unaffected. Adequate levels of
transactivation are required for infectivity in vivo support-
ing the notion that tax is an essential gene.
The injection of sheep with provirus 344 fulfills all the
requirements of a model system linking fields as diverse as
molecular biology, virology and pathogenesis. Therefore,
clone 344 has been used to construct a series of derivative
proviruses harboring mutations or deletions in different
parts of the genome. As expected, large deletions within
the structural or enzymatic gag, pol or env genes destroy
infectivity in vivo [83,112]. Interestingly, co-infection of
sheep with two defective recombinants can generate a rep-
lication-competent and pathogenic virus by homologous
recombination in vivo. As mentioned earlier (see section
2), several residues/regions in the viral genome are essen-
tial for infection: E303 of Tax, Y197 of the TM ITAM
motifs and the MHR domain of CA [112,162]. Consider-
ing that genetic information is highly condensed in the
proviral genome, it is surprising to identify a large domain
within the provirus that is dispensable for infectivity in
vivo. Indeed, the deletion of the region which expands
from the end of the env gene to the splice acceptor site of
the tax/rex mRNA does not impair infectivity ([83] and
unpublished results). Since these sequences correspond
respectively to the third and second exons of the R3 and
G4 mRNAs, it appears that these genes are not essential for
infectivity in vivo. Similar conclusions were drawn from
HTLV mutant proviruses deleted in the ORFs encoding the
p12I and p13II/p30II orthologs of R3 and G4 [240-242].
Importantly, the R3/G4 deletion greatly interferes with
the efficiency of BLV propagation and restricts pathogene-
sis [170,172]. Very recently, however, one out of 20 sheep
infected with a R3/G4 mutant developed a lymphoma
after 7.5 years of latency, demonstrating that the deleted
sequences are not strictly required for pathogenesis (Flor-
ins et al, in preparation). It does remain that the integrity
of the R3/G4 genes significantly contributes to disease fre-
quency and latency (see Table 1).
The BLV 344/sheep system has been instrumental for
unraveling determinants of the viral replication cycle.
Binding of the viral envelope complex to the target cell
membrane leads to a process of fusion, allowing subse-
quent viral entry. The fusion mechanism can be repro-
duced  in vitro by co-cultivation of fibroblasts or
lymphocytes expressing Env proteins at their surface and
target cells like CC81, leading to polykaryocytosis [156].
The fusion process is mediated by the oblique insertion of
the TM aminoterminal peptide into the lipid bilayer of the
cell membrane. Forcing the peptide to adopt a parallel ori-
entation by mutation abrogates fusion in cell culture and
infectivity in vivo [83]. In contrast, replacement of the pep-
tide by the corresponding residues derived from SIV (sim-
ian immunodeficiency virus) yields a fully fusion-
competent envelope. However, a virus carrying this muta-
tion lacks infectivity, suggesting that additional con-
straints are operative in vivo. What is even more surprising
Table 1: Summary of unexpected conclusions deduced from the BLV/sheep model
Fusion-deficient viruses can propagate at wild type levels
A transformation-deficient tax mutant is leukemogenic in sheep
A large region between the env and R3 genes is dispensable for infectivity and viral spread
Deletion of R3/G4 affects but does not abrogate pathogenicity
Increasing LTR promoter activity decreases viral spreadRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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is that TM mutants (i.e. A60V and A64S) that are deficient
for cell fusion in vitro nevertheless support viral infectivity
in vivo [154]. And, very unexpectedly, these mutant viruses
can propagate at wild-type levels and are pathogenic in
sheep (see Table 1). Since the A60V and A64S mutants are
also impaired for SU/TM interaction, it seems that integ-
rity of the envelope complex is not strictly required in vivo.
If the cell fusion processes in vitro and in vivo are indeed
impaired equally by these mutations, then the findings
offer the unexpected suggestion that BLV replicates by
mitotic division of the infected cell rather than by de novo
envelope-cell receptor mediated infectious cycle.
The tax gene is assumed to be a major factor required for
viral replication and pathogenesis. Tax activates LTR-
directed transcription and immortalizes primary cells in
culture [190,191,199,202,243]. The two activities of Tax
can be dissociated; for example, mutations in the zinc fin-
ger abrogate transactivation without altering immortaliza-
tion [194]. Conversely, substitution of the two major
phosphorylation sites in Tax does not alter its transcrip-
tional activity but destroys its oncogenicity in REF cells
[200]. As illustrated by the defect seen with provirus 395,
Tax's transactivation activity is required for viral infectivity
in vivo. In contrast, a provirus (Tax106+293) harboring
mutated phosphorylation sites remains infectious and
propagates at wild-type levels in sheep. In addition, the
Tax106+293 mutant is pathogenic despite a loss in its
ability to transform primary cells in vitro [201] (see Table
1). These findings suggest that a deficiency in Tax onco-
genic potential as revealed by the REF immortalization
does not correlate with leukemogenesis in vivo.
As previously mentioned, the BLV transcriptional pro-
moter located in the 5' LTR contains suboptimal binding
sequences for the CREB transcription factor. Remarkably,
the cyclic-AMP responsive site (CRE) consensus
"TGACGTCA" is never strictly conserved in any viral 21 bp
element which invariably contains an imperfect substitu-
tion (for example, AGACGTCA, TGACGGCA, TGAC-
CTCA). Restoring a perfect CRE sequence into the
promoter increases LTR (long terminal repeat) promoter
activity, as expected [88]. However, the proviral loads are
drastically reduced in sheep infected with a virus harbor-
ing this type of change (see Table 1). It is tempting to spec-
ulate that BLV may have evolved a self-attenuating process
(perhaps for purposes of escaping immunosurveillence)
which encourages the virus to maintain a less active pro-
moter through suboptimal use of the CRE-dependent
pathway. If this speculation is correct, then one thought is
that transcriptional repression of viral expression may be
a key factor which regulates viral persistence and spread.
As mentioned in section 2, the activity of the viral LTR is
also thought to be regulated by E-box motifs which over-
lap the CRE sites [88,89]. However, an E-box mutant virus
is infectious, replicates to wild-type levels and is patho-
genic in sheep. These observations question the clear sig-
nificance of the E-box motif in vivo [88] (and unpublished
results).
Collectively the experimental findings from BLV research
emphasize the dichotomy between subgenomic in vitro
results and counterpart findings achieved using replicat-
ing viruses in vivo; they reinforce the critical need to per-
form pathogenesis studies in vivo.
5. Mecanisms of leukemogenesis
BLV is an exogenous virus which integrates randomly in the 
cellular genome
Viral infection is followed by a polyclonal expansion of a
large and diverse population of lymphocytes harboring
one to five integrated proviruses [122,123,244-246]. At
later stages, a few cell clones predominate and the popu-
lation evolves towards monoclonality in assays of viral
integration. Proviral integration thus appears to be man-
datory for the viral life cycle, although each integration
event may not be perfect and on occasions some
sequences are deleted [183,184,247]. In fact, these rela-
tively frequent deletions typically affect the central struc-
tural genes and yield dead-end viruses that are unable to
replicate  in vivo [83,184]. The emergence of these
deletants might be a fortuitous consequence of viral repli-
cation following mistakes during reverse transcription,
recombination or integration. However, the frequency at
which these deletions occur in tumor samples suggests
that they provide a selective advantage to the infected cell.
In rare cases, it is even possible that a deleted provirus is
the sole integrant within the host cell genome. However,
it appears that at least one copy of the full-length BLV pro-
viral genome is maintained in each animal throughout
the course of the disease [185]. Whether these replication-
competent viruses complement the deletants, as observed
for spleen focus-forming virus, is unknown. The defect
within the proviruses is a consequence either of large dele-
tions or of point mutations, but is not due to insertion of
cellular sequences [248,249]. Finally, BLV provirus inte-
grates at random sites and, therefore, does not transform
cells by insertional mutagenesis, as observed in ALV-
induced tumors (Avian Leukosis Virus) [250,251].
Low levels of viral expression are detected in vivo
An apparent paradox of BLV infection is that leukemogen-
esis proceeds in the absence of viral expression. In fact,
lack of expression pertains to the large majority of detect-
able virus-infected cells [252,253]. The first evidence is
that BLV virions or viral proteins cannot be directly
detected in the peripheral blood by any currently availa-
ble technique (ELISA, flow cytometry, immunoprecipita-
tion or western blotting). Second, viral transcripts from
peripheral blood lymphocytes or tumors can only beRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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amplified by means of very sensitive RT-PCR techniques
[79,180,254,255]. Third, using flow cytometry cell sorting
and subsequent RT-PCR, only about one B lymphocyte
out of 10,000 is found to express tax/rex mRNA during
persistent lymphocytosis. Fourth, only rare cells in the
peripheral blood (1 in 50,000) contain enough BLV tran-
scripts to be readily identified by in situ hybridization
[256,257]. A potential repression mechanism of viral
expression involves a plasma factor related to fibronectin
[258-260] and inhibited by a platelet lysate [261]. How-
ever, expression of BLV in samples of whole blood from
BLV-infected cattle is activated immediately upon incuba-
tion at 37°C in the absence of any exogenous factors
except for anticoagulants or the removal of blood cells
from plasma [262].
As early as in 1969, Miller [69] showed that cultivation of
infected peripheral blood mononuclear cells leads to
expression of viral antigens. This process has been exten-
sively characterized to identify the involved pathways: it
appears that concanavalin A [263,264], phytohemaggluti-
nin (PHA) [256,265], lipopolysaccharide (LPS)
[179,266], phorbol esters (PMA) and calcium ionophores
[24,267,268] activate viral protein synthesis. The presence
of T cells increases [264,269,270], but is not strictly
required for viral expression by the infected B lym-
phocytes. As revealed by a series of relatively specific
inhibitors, the metabolic pathways involved in viral
expression include protein kinase C, calmodulin and
intracellular calcium mobilisation. More physiological
stimuli of viral expression include cross-linking of mem-
brane IgM or interactions with CD40 ligand, mimicking
BCR and T cell activation, respectively [243,256,268].
Finally, viral transcription is activated by components of
fetal bovine serum.
Altogether, these data indicate that viral expression can be
augmented by molecules that mimic B cell activation by
immune cells. As presented in this paragraph, the tradi-
tional and dogmatic model postulates that cells are
latently infected and express viral proteins only upon
transient ex vivo cell culture. This concept faces a series of
objections and we propose another model in section 6.
Altered gene expression of cytokines
Interleukins: IL2, IL6, IL10 and IL12
A first described cytokine network interconnects inter-
leukin-10 (IL-10), viral expression and B-cell proliferation
in BLV-infected cattle. IL-10 mRNA is over expressed in
cows with persistent lymphocytosis [271,272]. In cell cul-
ture of PBMCs, IL-10 inhibits expression of COX-2 as well
as antigen-specific cell proliferation. IL-10 suppresses syn-
thesis of a macrophage-derived COX-2 product, prostag-
landin E2, that stimulates virus expression [273,274].
Although reported data on IL2 expression during the
course of BLV-infection are discordant, it is agreed that
elevated levels of this cytokine are synthesized in
mitogen-stimulated PBMCs from asymptomatic and PL
cattle [225,264,275-278]. Furthermore, in isolated B lym-
phocytes from PL cows, IL-2 increases viral CA protein
synthesis, IL-2 receptor expression, and triggers prolifera-
tion.
T cells isolated from lymph nodes and peripheral blood of
BLV-infected cattle express IL-2 mRNAs [279]. However,
the amounts of IL-2 mRNAs are significantly reduced in
CD4+ T cells from PL cows as compared to controls; on
the other hand, no significant differences in the frequen-
cies of CD4+ T cells expressing these cytokine mRNAs are
observed.
Although IL-6 mRNAs are barely detectable in fresh B cells
from PL cows, transcripts encoding this cytokine are
strongly and rapidly upregulated after cell culture [280].
Furthermore, levels of IL-6 are significantly higher in the
sera of BLV infected cows with PL as well as in PBMC cul-
tures following in vitro exposure to BLV antigens [281].
When exogenous IL-6 is added to infected cells in vitro,
viral expression is strongly suppressed, suggesting that IL-
6 plays a contributory role to viral latency.
Finally, elevated levels of IL-12 in asymptomatic and PL
cattle are expressed by mitogen-stimulated PBMC [282].
However, IL-12 p40 mRNA expression is significantly
decreased in PL cattle compared to aleukemic animals
[283].
TNFα
The role of tumour necrosis factor alpha (TNFα) in BLV
replication has clearly been demonstrated in TNF-/- knock-
out mice [284]. In sheep inoculated with BLV, expression
of TNFα receptor type 1 mRNA (TNF-R1) is down-regu-
lated while TNF-R2 mRNA remains constant. BLV-
infected PBMCs express membrane-bound TNFα and pro-
liferate in response to TNFα [285,286]. Furthermore,
TNFα expression is higher in sheep that resist BLV infec-
tion after vaccination [287].
In BLV-infected cattle, the mean mRNA expression level
for TNF-α is higher in the spontaneously proliferating and
antigen-induced PBMC population [271,272,281,288].
When exogenous TNF-α is added to BLV infected cells in
vitro, viral expression is strongly suppressed. Cells isolated
from PL cattle exhibit increased proliferative responses in
the presence of recombinant bovine TNF-α [289] and
express significantly higher TNF-R2 mRNA levels
although no difference is found in TNF-R1 mRNA levels.
Most cells expressing TNF-R2 are CD5+ or sIgM+ cells and
are less prone to TNFα-induced apoptosis [285].Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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IFN-γ
As expected by its antiviral activity, recombinant bovine
IFN-γ suppresses replication of ovine BLV-infected cells in
vitro [290]. In addition, sheep, which show augmented
mRNA expression of IFNγ, have lower proviral loads
[291]. When BLV-infected cattle are inoculated intraperi-
toneally with recombinant bovine IFN-γ,  γδ T cells
increase soon after a period of transient fever whereas the
number of BLV-infected B lymphocytes remains low dur-
ing one week [292]. This experiment thus directly illus-
trates the potency of IFNγ to inhibit viral spread.
IFNγ mRNA is detected in the T-cell population isolated
from lymph nodes of BLV-infected cattle [279,282]. In
PBMCs, IFN-γ mRNA expression increases 4 weeks after
infection [293] but the antiviral activity remains intrigu-
ingly unaffected [294]. In aleukemic cattle, IFNγ mRNA
expression is significantly increased compared to those in
cattle with persistent lymphocytosis [283]. Furthermore,
IFN-γ is elevated in pokeweed mitogen-stimulated cells
from asymptomatic cattle but not from PL animals [282].
Recently, another form of interferon, IFN-τ, was reported
as a potential anti-viral protein in cattle [295].
Host cell genetics
BLV-induced leukemogenesis is preceded by a long lasting
chronic disease characterized by accumulation of genetic
modifications such as mutation of p53 within the host
genome [296-299]. Approximately half of the solid
tumors induced by BLV in cattle contain a mutated p53
gene while very few mutations are found in preneoplastic
B cells. These mutations interfere with essential p53 func-
tions required for transactivation and suppression of cell
growth [299]. In addition, the ratio of Bcl2 to Bax which
is believed to predetermine the susceptibility to a given
apoptotic stimulus is increased at advanced stages of dis-
ease in cattle [300]. In contrast, the p53 gene is not
mutated at any stage of disease in sheep [301].
Tumors cells accumulate clonal abnormalities and are
hyperdiploid [302]. The most common aberrations are
the acquisition of additional small chromosomes, tri-
somy, Robertsonian translocations and isochromosome
rearrangements. Whether these abnormalities are
required to achieve full malignancy or are just bystanders
of transformation is currently unknown. However, it is
likely that these chromosomal alterations acquired during
a long multistep process provide a selective growth advan-
tage to the tumor cells.
The genetic profile of the host genome also predisposes to
tumor development [303]. A major factor involved in
clinical progression of BLV-infected animals is mediated
by the bovine major histocompatibility complex (BoLA)
[304,305]. Genetic resistance and susceptibility to persist-
ent lymphocytosis (PL), have been mapped to structural
motifs in bovine MHC DRB3 (class II) alleles [306]. Hap-
lotype DQA*12-DQB*12-DRB2*3A-DRB3.2*8 is associ-
ated with a risk factor for subclinical progression to PL in
BLV-infected animals, whereas DQA*3A-DQB*3A-
DRB2*2A-DRB3.2*11 correlates with resistance [307].
Animals with the PL-resistance associated DRB3.2*11
allele have significantly fewer BLV-infected B cells than do
age- and seroconversion-matched cows with DRB3 alleles
associated with susceptibility to PL [308]. Furthermore,
another polymorphism in the promoter region of TNF-α
gene (-824G allele) may contribute to the progression of
lymphoma in BLV-infection [309]
In sheep, genetic predisposition to development of leuke-
mia correlates with a particular MHC-II DRB1 allele. The
Arg-Lys (RK) and the Ser-Arg (SR) at positions 70/71 of
the OLA-DRβ1 domain are associated with resistance and
susceptibility, respectively, to development of lymphoma
[310]. Higher levels of IFN-γ are found in animals with
RK/RK genotype [311] most probably modulating disease
progression.
The susceptibility to the polyclonal expansion of BLV-
infected B lymphocytes is thus associated with specific
alleles of the major histocompatibility complex system.
Host humoral and cytotoxic immune responses
Natural or iatrogenic transmission of BLV primarily
involves the transfer of infected cells via blood or milk
[8,308]. The processes occurring after this primary infec-
tion still remain obscure. One of the earliest indications of
infection is the onset of a humoral anti-viral response at
about 1–8 weeks post-inoculation [308,312,313]. Anti-
bodies recognizing epitopes from structural (envelope
gp51 and capsid p24) and regulatory proteins (Tax and
Rex) are synthesized at high titers. Some of these antibod-
ies are directly lytic for BLV-producing cells [314]. The
level of antibody-mediated cytolytic activity increases
with progression of the disease towards the acute phase
[315].
Almost concomitant with the early seroconversion period,
cytotoxic T-lymphocytes (CTL) specific for Tax and Enve-
lope epitopes appear in the peripheral blood [147,285].
Compared to humans, a peculiarity of cattle is that γδ T-
lymphocytes are major players in this cytotoxic response
[316]. BLV infection also triggers both a virus-dependent
and a virus-independent CD4 helper T cell response
[144,317,318].
It thus appears that a very active humoral and cytotoxic
immune response is initiated soon after BLV infection
(reviewed in [285,319]). Importantly, these anti-viralRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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activities amplify and persist throughout the animal's life
indicating that the immune system is permanently stimu-
lated by BLV antigens. The persistence of this immune
response is relatively unexpected for a chronic infection,
at least if associated with a latent virus. However, cytotoxic
and helper associated functions weaken in BLV-infected
animals, as the disease progresses, as supported by a lower
spontaneous recovery from Trichophyton verrucosum
[285,320]
6. Cell dynamics of viral infection
Is BLV silent?
Although BLV expression is detected in a minority of via-
ble cells, a strong cytotoxic and humoral immune
response is induced within the infected host. Experimen-
tal evidence (i.e. in situ hybridization, flow cytometry, RT-
PCR) favors a model postulating that the virus is latent in
the very large majority of detectable cells (i.e. those that
escape from immune response and can be isolated and
observed ex vivo). The latency of BLV in vivo and its reacti-
vation upon ex vivo culture thus became a standing
dogma. There are however a series of caveats in this
model. Indeed, the maintenance of a vigorous anti-viral
immune response in infected animals indicates that some
degree of virus expression must occur in vivo. Further-
more, BLV transcription can even be detected in samples
of whole blood upon incubation at 37°C without addi-
tion of any exogenous factor except anticoagulants [262].
Then, why would this process not be ongoing continu-
ously in infected cells in vivo? If anticoagulants do not acti-
vate viral expression, it is unlikely, although not
impossible, that the simple removal of blood would be
sufficient to induce BLV transcription. Alternatively, we
favor the idea that viral expression occurs permanently in
a subpopulation of infected cells, which are very effi-
ciently killed by the immune system. The cytotoxic and
humoral responses are however unable to destroy cells in
which viral transcription is completely silenced.
How does the virus replicate?
Viral replication occurs via the replicative cycle after
expression of virions able to infect novel target cells. Alter-
natively, the integrated proviruses can expand by mitosis
of the host cell by a process referred to as clonal expansion
[321]. Semiquantitative inverse PCR amplification of the
cellular sequences flanking the BLV provirus has revealed
that the viral load results almost exclusively from clonal
expansion of infected cells [246]. Importantly, the prema-
lignant cellular clones from which the tumor originates
can be detected as early as a few weeks after experimental
infection. In fact, the latency period preceding onset of
leukemia/lymphoma is characterized by a fluctuation in
the abundance of different cellular clones harboring an
integrated provirus. Malignancy of a given clone correlates
with the accumulation of somatic mutations revealing a
decrease in the genetic stability of the expanding infected
cell. During the asymptomatic phase, most of the proviral
load is sustained by mitosis of the infected cell. Efficient
virus replication and infection of new target cells via viri-
ons and/or virological synapses seem to occur mostly, if
not almost exclusively, during a very short period follow-
ing viral inoculation (so-called primary infection). How-
ever, it is still possible that the replicative cycle is ongoing
continuously but the net outcome of this process does not
contribute significantly to the observed viral load, because
of an efficient immune response.
Two key and related questions remain to be solved: why is
the abundance of the infected cell clones fluctuating? And
what is the driving force of the clonal expansion process?
Based on the extensively described oncogenic properties
of Tax, our tenet is that this virally encoded protein trig-
gers cell proliferation.
Is BLV inhibiting apoptosis?
When peripheral blood mononuclear cells from BLV-
infected sheep are transiently maintained in culture for a
few hours, the levels of B cell apoptosis are reduced com-
pared to normal controls [322,323]. The most straightfor-
ward interpretation is that BLV interferes with
spontaneous apoptosis of B lymphocytes. This process
requires at least in part a caspase 8-dependent pathway
regardless of viral infection [324]. Pharmaceutical deple-
tion of reduced glutathione (namely, gamma-glutamyl-L-
cysteinyl-glycine [GSH]) by using ethacrynic acid or 1-pyr-
rolidinecarbodithioic acid specifically counters the inhibi-
tion of spontaneous apoptosis conferred indirectly by
protective BLV-conditioned media; conversely, exoge-
nously provided membrane-permeable GSH-monoethyl
ester restores cell viability in B lymphocytes of BLV-
infected sheep. Most importantly, intracellular GSH levels
correlate with virus-associated protection against apopto-
sis but not with general inhibition of cell death induced
by polyclonal activators, such as phorbol esters and iono-
mycin. Similar evaluations of spontaneous apoptosis in
cattle yielded a very broad range of spontaneous apopto-
sis mainly depending on the experimental conditions
[97,325,326].
A major problem with ex vivo experiments is that it is
never possible to perfectly replicate the situation prevail-
ing in vivo. Even under the culture conditions that most
closely mimic the natural medium (such as culture of
heparin-containing blood), interpretations of data will
always face experimental objections. For instance, when
lymphocytes are isolated from a BLV-infected sheep and
maintained for a few hours in culture, almost all cells
expressing the major viral capsid protein p24gag fail to
undergo apoptosis (Figure 4). This observation fits well
with previous reports showing that B-lymphocytes fromRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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infected sheep are less prone to apoptosis compared to
control cells [322,323]. However, an alternative interpre-
tation is that cells that spontaneously express CA antigen
are cleared in vivo and therefore cannot be detected ex vivo.
Cell kinetics in vivo
Several markers of proliferation (PCNA, KI67 and myc) are
overexpressed in B lymphocytes from tumors and PBMCs
isolated from animals with PL, suggesting an increased
replicative capacity of these cells [327-329]. However,
lymphocyte homeostasis is the result of a critical balance
between cell proliferation and death. Disruption of this
equilibrium can lead to the onset of leukemia. Thus an
increase in lymphocyte number can be potentially
explained by either one or both of the above parameters.
To further gain insight into the processes mediating
pathogenesis, it is necessary to determine the kinetic
parameters which sustain the dynamics of the different
cell populations in infected animals. The proliferation
rates in BLV-infected and healthy sheep were initially
determined using intravenous injection of bromodeoxyu-
ridine (BrdU). This in vivo approach revealed that B-lym-
phocytes are proliferating significantly faster in BLV-
positive asymptomatic and lymphocytic sheep than in
uninfected controls (average proliferation rate of 0.020
day-1 versus 0.011 day-1), meaning that an excess of 0.9 %
cells (the difference between 2 and 1.1%) are produced by
proliferation each day [330]. The difference in the prolif-
eration rates becomes even more evident at the terminal
neoplastic stage of the disease (proliferation rate increases
by up to tenfold). Cells in S/G2/M then also appear in the
peripheral blood (our unpublished results) similar to
findings documented for acute cases of human non-viral
leukemia [331]. In contrast, the death rates of the BrdU-
positive cells are not significantly different between
aleukemic BLV-infected and control sheep.
In the natural host, BLV-infected cattle, the cell prolifera-
tion rates in asymptomatic and control animals are not
significantly different [325]. Surprisingly, the PL stage is
characterized by a decreased B cell turnover resulting from
a reduction of cell death as well as from an overall impair-
ment of proliferation. Paradoxically, an excess of B lym-
phocytes in the peripheral blood in PL animals correlates
with a reduction of cell proliferation, suggesting that a
mechanism of feedback regulation controls lymphocyte
homeostasis. Of note, the lymphocyte turnover is also
reduced in other lymphoaccumulative diseases such as,
CLL (chronic lymphocytic leukemia), a B CD5+ chronic
leukemia in human (J. Defoiche, submitted). The reduced
dynamic parameters measured in cattle thus contrast with
the accelerated kinetics observed in experimentally
infected sheep. Whether these observations relate to the
differences in disease acuteness in the two host species
remains a tempting but still open assumption.
Cells expressing viral proteins cannot be directly observed
in the peripheral blood of the infected animals at any
stage of the disease. However, viral expression can be
induced upon transient short term culture. Surprisingly,
very few (if any) cells spontaneously synthesizing CA anti-
gen undergo proliferation in vivo [325,330]. Amongst all
infected cells proliferating in vivo as measured by BrdU
uptake, none is found to express viral protein. Since lym-
phocytes synthesizing p24gag are spared from apoptosis ex
vivo, p24+BrdU+ double positive cells are not lost during
culturing but appear to have been eliminated in vivo. If we
postulate that viral expression and cell activation are
closely linked, as widely illustrated in the literature, the
lack of p24+BrdU+ double positive cells then reveals a
very efficient negative selection which occurs in vivo.
Another non-exclusive interpretation would be that only
a subpopulation of infected cells is allowed to proliferate
(i.e. incorporate BrdU) provided that no viral proteins are
expressed. However, this model does not fit with the pro-
gressive accumulation of provirus-positive cells, if prolif-
eration is triggered by a viral protein. What would indeed
be the selective advantage of a cell carrying a completely
silent provirus?
Whatever the involved mechanisms, these kinetic studies
cast light onto a very active process of immune selection
directed towards proliferating infected cells that express
an integrated provirus.
Lymphocyte trafficking in lymphoid organs
Homeostatic regulation of lymphocyte numbers in the
peripheral blood results from a series of physiological fac-
tors, of which cell proliferation and death are only partial
components. Indeed, kinetics of a cell population is also
influenced by recirculation to lymphoid organs, in which
proliferation is thought to primarily occur, at least under
normal conditions. In this context, experiments based on
BrdU kinetics lead to an apparent discrepancy: the imbal-
ance created by the net increase in proliferation in the
absence of compensating cell death is estimated at 7 % per
day [330]. Since this considerable proliferation rate is not
reflected by a corresponding increase in the lymphocyte
numbers, other regulatory mechanisms including altera-
tion of recirculation as well as a massive elimination of
cells in other tissues could play a role. To test these
hypotheses, B cell migration from blood to lymph and
back from lymph to blood has been traced with the car-
boxyfluorescein diacetate succinimidyl ester (CFSE), a flu-
orescent dye that labels proteins via their NH2 terminal
ends. Direct intravenous administration of CFSE into
sheep achieves remarkable labeling indexes: more than
98% of peripheral blood leukocytes become fluorescentRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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Cells expressing CA are not prone to undergo apoptosis Figure 4
Cells expressing CA are not prone to undergo apoptosis. Dot plot resulting from a flow cytometry analysis of periph-
eral blood mononuclear cells isolated from a lymphocytic BLV-infected sheep and transiently cultivated during 24 hours. Cells 
were labeled with a monoclonal antibody specific for the viral major capsid protein p24gag (X axis: viral expression) and by 
TUNEL (Y axis: apoptosis).
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within seconds [332]. Since CFSE is extremely unstable in
aqueous solution, labeling is very short lived, making it
feasible to track lymphocyte migration from the periphery
through the lymph node in vivo. While most studies of
lymphocyte recirculation and homing have been done in
rodents, the sheep model offers the opportunity to study
the recirculation of lymphocytes through tissues by direct
cannulation of individual lymphatic vessels [333-335]
(Figure 5). Using this approach, it has been shown that B-
lymphocytes from BLV-infected and control sheep recircu-
late with similar rates [336]. In contrast, the proportions
of labeled B cells in the peripheral blood decrease signifi-
cantly faster in infected sheep. Combined with another
parameter (the halving of the fluorescence intensity upon
cell division), it was possible to calculate proliferation
and death rates [337]. These calculations indicate that B
cells labeled with CFSE in the peripheral blood undergo
massive destruction during chronic BLV infection of sheep
[336]. Importantly, the CD11b subpopulation accounts
for the difference in CFSE kinetics in BLV-infected sheep
(i.e. the turnover of CD11b + B cells is increased), provid-
ing a rationale favoring the accumulation of these cells
during pathogenesis.
Collectively, quantification of the dynamic parameters
deduced from BrdU and CFSE kinetics shows that the
excess of proliferation in lymphoid organs can be com-
pensated by increased death of the peripheral blood cell
population. An important issue that remains to be clari-
fied is to identify the anatomic site required for this cell
destruction. In this context, our recent experiments
revealed that the spleen is a major lymphoid tissue regu-
lating infected cell dynamics [338]. Indeed, the cell death
rates pertaining to the peripheral blood cells of BLV-
infected and control sheep are similar after splenectomy,
revealing a key role of the spleen in B-lymphocyte dynam-
ics.
Collectively, recent data show that the B lymphocyte turn-
over is accelerated in BLV-infected sheep. Amongst a series
of plausible hypotheses that cannot be formally excluded,
one of the possible models is that the increased turnover
results from an activated immune response directed
towards the virus. Continuous expression of viral antigens
could indeed exacerbate proliferation of virus-reactive
immune cells either directly or via cytokines with poten-
tial expansion of BLV-infected B lymphocytes. Excessive
proliferation of uninfected B-lymphocytes in response to
BLV early infection has recently been documented clearly
[245]. In addition, uninfected B lymphocytes also accu-
mulate above normal levels during persistent lymphocy-
tosis. Whether a similar anti-viral process is also
responsible for expansion of BLV-infected B cells is pres-
ently unknown. It would be interesting to determine the
B cell receptor specificity of the infected B lymphocytes.
For instance, IgGs of CLL leukemic B cells are targeted
towards autoantigens or common bacterial infections
(DNA, glycerophospholipid, lipoprotein, and polysaccha-
rides), permitting expansion of the transformed clone.
Arguments against this hypothetical mechanism of indi-
rect viral spread include the absence of selective growth
advantage conferred to the infected cells. Why would a
viral antigen-specific B cell be preferentially infected by
the virus? We therefore favor a model in which the virus
plays an active role by continuously expressing viral pro-
teins, like the Tax oncogene, able to promote cell prolifer-
ation and transformation (Figure 6). Tax expression could
be permanent, provided that cells escape from immune
response (which is a rare event), or initiated indirectly via
cellular activation. Concomitantly, Tax expression would
also stimulate the host's anti-viral immune response,
which in turn would clear the infected cells. Escape from
the immune response could be due to an uneven distribu-
tion of viral proteins between the daughter cells. Alterna-
tively, shut off of viral expression possibly by epigenetic
processes (e.g. histone acetylation, histone methylation or
DNA methylation as described [100,339,340]) or involv-
ing a putative viral accessory factor (such as HBZ for HTLV
[341,342]) would be a prerequisite allowing a minority of
these cells to escape from immune response. Since the
presence of doubly spliced tax/rex transcripts in the cyto-
plasm precedes that of other viral mRNAs [179], it is pos-
sible that a subpopulation of cells would exclusively
express the Tax protein at least during a short interval. In
this model, Tax would be the driving force providing a
selective advantage and leading to clonal expansion of the
infected cells. Permanent expression of Tax would not
even be required in each mitotic cycle if cell activation is
maintained by a hit and run mechanism as previously
proposed by Mitsuaki Yoshida in 1986 [343]. A variety of
other processes involving for instance NFκB may also
account for ongoing mitotic replication. Finally, even if
this activation cannot persist through divisions, it is easily
conceivable that clonality results from a population of
cells having undergone different numbers of mitotic
cycles (i.e. a "ladder pattern") instead of a classical pyra-
mid shape of the progeny population. The heterogeneity
of the telomere lengths observed in clonal populations of
tumor cells supports the latter hypothesis (our unpub-
lished results).
Since very few lymphocytes expressing viral proteins can
be detected directly in vivo, the frequency of infected cells
which survive the host immune pressure is low. Also, this
process would only marginally affect the very large major-
ity of infected cells containing a silent virus (or a modestly
expressed virus). The net outcome of this model would be
a global stability of the proviral loads with some fluctua-
tions of individual clones, as revealed by long term fol-
low-up of proviral integration sites by ligation-mediatedRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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Canulation of mesenteric lymphatic vessels Figure 5
Canulation of mesenteric lymphatic vessels. The lymphatic vessels and the lymph nodes were colored by injection of 
Evans blue and dwelling catheters were inserted into the efferent lymphatics.
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Hypothetical mechanism of BLV replication Figure 6
Hypothetical mechanism of BLV replication. Normal B cell activation and proliferation depend on a variety of immune 
stimuli, involving the BCR (and possibly CD5, section 3), CD40 ligand expressed by T cells, various cytokines or even autoanti-
gens (see section 5). We hypothesize that BLV replication is initiated by these classical regulatory mechanisms because viral 
expression can be augmented by molecules that mimic B cell activation by immune cells. Tax expression precedes that of struc-
tural and enzymatic proteins and promotes entry into the cell cycle, providing a selective proliferative advantage of the infected 
cells (see section 4, The Tax transactivator). Uneven distribution of the viral proteins upon mitosis would generate two types 
of infected cells containing or not BLV antigens (see section 4, The envelope gene). Other processes might account for silenc-
ing of viral expression in one daugther cell such as a specific inhibition by a viral factor such as HTLV p30 or HBZ (still to be 
discovered for BLV). We think that BLV expression is ongoing continuously in vivo because viral transcripts are detected in 
whole blood immediately upon incubation at 37°C in the absence of any exogenous factors (see section 5, Low levels of viral 
expression are detected in vivo). Virus-positive cells would be destroyed by the immune response (see section 5, Host 
humoral and cytotoxic immune responses) or would undergo apoptosis via intrinsic or extrinsic pathways (section 6: Is BLV 
inhibiting apoptosis?). These cells would thus permanently stimulate the host's immune response. Cells in which viral expres-
sion has been shut off or lacking viral antigens after mitosis would enter a resting stage in the absence of Tax and/or immune 
stimulation. These cells surviving destruction by the immune response can be isolated and observed ex vivo.
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PCR. Although the mechanism is still unknown, varia-
tions in the abundance of provirus-positive cell clones
could be due to differential antigen stimulation or to
modulation of the proportions of individual progeny cells
to express virus. Hence, cells isolated from sheep at termi-
nal stages of the disease lose their ability to efficiently
express virus ex vivo even in the presence of potent poly-
clonal activators such as phorbol esters (our unpublished
results). Ultimately, a fully transformed cell clone con-
taining a deleted replication defective provirus can even
outgrow and induce leukemia [83].
A hypothetical model, which may also apply to HTLV
[344], is needed to reconcile the following experimental
findings which include the oncogenic potential of Tax, the
continuous stimulation of the immune system, the low
levels of detectable cells expressing viral proteins in vivo,
the apparent stability of individual proviral clones, and
the dynamic parameters of cell proliferation and cell
death. During BLV chronic infection, the host-pathogen
interplay is characterized by a very dynamic kinetics gen-
erating equilibrium between a virus attempting to prolif-
erate under a tight control exerted by the immune
response. In this model, the virus permanently transits
between a latent and transcriptionally active phase result-
ing in the progressive accumulation of viable infected
cells. Occurrence of somatic mutations associated with
genetic instability in these cells ultimately permits the out-
growth of a transformed clone, leading to leukemia.
7. Modulation of viral expression as therapy
In the absence of ex vivo cell culture, the infected lym-
phocytes apparently do not express any viral protein in
the peripheral blood and rest in the G0/G1 phase of the
cell cycle. These apparently quiescent cells may undergo
spontaneous cell proliferation and express virions upon
transient short-term culturing. Agents known to activate
immune cells polyclonally cause an increase in the
number of cells containing BLV RNA [345]. Viral expres-
sion may thus be induced by activation of the host cell
after immune-mediated stimulation.
It is possible that an inhibitory mechanism (or the
absence of a driving force) hampers viral gene expression
in vivo. Persistence of infected cells would thus be permit-
ted under the restrictive condition where viral proteins are
not expressed (or at least at a level undetectable by the
immune system). Evidence for a very strong immune
response is supported by the presence of virus specific
cytotoxic T cells and by high titers of cytolytic antibodies.
However, the lack of viral expression in a large proportion
of infected cells does not allow efficient clearance by the
immune system. Concomitantly, virus infection might
also correlate with inhibition of the apoptotic processes,
generating a reservoir of apparently latent cells. In this
context, we aimed at evaluating the therapeutic effective-
ness of a strategy based on the induction of viral and cel-
lular gene expression. Among a number of
methodological approaches, modulation of chromatin
condensation, which is an essential component of the
gene expression process, can be achieved by interference
with the level of histone acetylation [346]. This mecha-
nism results from an intrinsic balance between the activity
of two families of antagonistic enzymes, histone deacety-
lases (HDAC) and histone acetyltransferases, respectively
removing or incorporating acetyl groups into core his-
tones (Figure 7). Although this model is probably over-
simplified, acetyl removal by HDACs restores a positive
charge to the lysine residues in the histone N-terminal
tails and is thought to increase the affinity of histones for
DNA, leading to transcriptional repression. Conversely,
impairment of HDAC function with specific HDAC inhib-
itors activates both cellular and viral gene transcription.
Among a growing list of HDAC inhibitors, valproate (the
sodium salt of 2-propylpentanoic acid) offers a series of
advantages [347]. Widely used for several decades in treat-
ing epilepsy, this short-chain fatty acid has a very high
bioavailability, exhibits very low toxicity in adults and,
with a half life of 16–17 hours, has suitable pharmacoki-
netic properties in vivo. Therefore, valproate has been
selected to evaluate the effectiveness of gene activation
chemotherapy in leukemic sheep. Indeed, valproate effec-
tively activates BLV gene expression in transient transfec-
tion experiments and in short-term cultures of primary B-
lymphocytes [339]. In vivo, valproate administration, in
the absence of any other cytotoxic drug, is efficient for the
treatment of leukemia/lymphoma in sheep, demonstrat-
ing the proof-of-concept of a therapy that targets the
expression of viral and/or cellular genes. Interestingly,
over a long term period, valproate treatment alters neither
the cell numbers in control sheep nor other lymphocyte
populations in BLV-infected animals, revealing a relative
innocuousness of the therapy.
The mechanism by which valproate specifically decreases
the number of leukemic cells remains to be determined.
Amongst numerous hypotheses, we propose a model
based on transient activation of cellular and/or viral
expression leading to apoptosis by intrinsic (for instance
dependent on mitochondrial regulated checkpoints) or
extrinsic mechanisms related to membrane-bound recep-
tors (Fas, TRAIL,) [348-350]. It is possible that the
involved mechanisms are completely independent of viral
infection as indicated by our ongoing experiments in mes-
othelioma and chronic lymphocytic leukemia cells (F.
Vandermeers and A. Bouzar). Alternatively, a very attrac-
tive model would include the induction of viral expres-
sion and destruction by the immune response.Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
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Based on the numerous similarities between BLV and
HTLV, we propose to investigate the therapeutic potential
of a valproate treatment in TSP/HAM and ATL. Indeed,
there are presently no satisfactory therapies for these dis-
eases so far. Palliative treatments for HAM/TSP include
steroids to decrease inflammation [351-353]. Attempts to
treat HAM/TSP by interfering with cell invasion into the
CNS using inhibitors of matrix metalloproteinases [354]
have been unsuccessful. Similarly, other strategies aimed
at inhibiting cell activation and/or viral replication with
cytokines (IFN-α or -β) [353] or anti-viral compounds
[355-358] did not show sufficient efficacy. ATL patients
have a very poor prognosis because of intrinsic chemore-
sistance and severe immunosuppression. Non-targeted
combinations of chemotherapy (CHOP) yield primary
responses but lack a significant effect on complete remis-
sion and survival [359]. Besides promising new drugs
such as arsenic trioxide and proteasome inhibitors, addi-
tional therapies are needed. In this context, valproate-
based gene activation therapy should be considered.
8. Conclusion
BLV is the etiologic agent of enzootic bovine leukemia in
cattle, a disease which (depending on the part of the
world) is either eradicated or simply ignored. However,
the experimental infection of sheep with BLV provides an
interesting model of leukemogenesis. In particular, we
review here the viral genetic determinants required for
pathogenesis and present recent understanding of the
homeostatic regulation of leukemic B lymphocytes in
BLV-infected sheep. We also propose a novel therapeutic
concept targeting the expression of viral genes and involv-
ing the immune response. This strategy might also hold
promise for treating adult T cell leukemia (ATL) or human
Valproate, an inhibitor of deacetylases, activates gene transcription and induces apoptosis Figure 7
Valproate, an inhibitor of deacetylases, activates gene transcription and induces apoptosis. Reciprocal reactions, 
acetylation and deacetylation are catalyzed by histone acetyltransferase (HAT) and histone deacetylase (HDAC). Acetylation of 
chromatin leads to deconsendation and activates transcription of a subset of genes. Valproate induces hyperacetylation, acti-
vates BLV expression and triggers apoptosis in cell culture. Valproate treatment of sheep with leukemia/lymphoma reduces the 
number of tumor cells.
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T-lymphotropic virus-associated myelopathy/tropical
spastic paraparesis (HAM/TSP), diseases for which no sat-
isfactory treatment currently exists.
List of abbreviations
ALV: avian leukosis virus
AP3: adaptator-related protein complex 3
ATF: activating transcriptor factor
BCR: B-cell receptor
BLV: bovine leukemia virus
BrdU: bromodeoxyuridine
CA: capsid protein
CaMKIV: calmodulin-depend kinase IV
CDR: complementary determining region
CFSE: carboxyfluorescein diacetate succinimidyl ester
CLL: chronic lymphocytic leukemia
CRE: cyclic-AMP responsive element
CREB: CRE binding protein
CTL: cytotoxic T lymphocyte
EBL: enzootic bovine leukemia
FPPS: farnesyl pyrophosphate synthetase
HDAC: histone deacetylase
HIV: human immunodeficiency virus
HTLV-1: human T-lymphotropic virus type 1
IFN: interferon
IL: interleukin
IN: integrase
IRF: interferon regulatory factor
ITAM: immunoreceptor tyrosine-based activation motif
ITIM: immunoreceptor tyrosine-based inhibition motif
LTR: long terminal repeat
NC: nucleocapsid protein
NF-κB: nuclear factor κB
MA: matrix protein
MHC: major histocompatibility complex
PBMC: peripheral blood mononuclear cell
PCNA: proliferating cell nuclear antigen
PKA: protein kinase A
PL: persistant lymphocytosis
PTLV: primate T-lymphotropic virus
RBD: receptor binding domain
REF: rat embryo fibroblast
RT: reverse transcriptase
SDF-1: stromal cell-derived factor-1
SNV: spleen necrosis virus
SU: surface protein
TM: transmembrane protein
TNFα:tumor necrosis factor α
TTP: tristetraprolin
TxRE: tax responsive element
USF: upstream stimulating factor
Competing interests
The author(s) declare that they have no competiting inter-
ests.
Authors' contributions
NG, FV, HB, AN and AB carry out experiments of gene acti-
vation therapy on BLV-infected animals. AF, MB, CB and
JD worked on cell dynamics and viral infection. NG and
LW drafted the manuscript and AB, MR and RK partici-
pated to its design and helped to draft it.
All authors read and approved the final manuscript.Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 24 of 32
(page number not for citation purposes)
Acknowledgements
We would like to warmly thank KT Jeang for helpful suggestions and for 
very careful editing of this manuscript. This work was supported by the 6th 
framework program INCA project of the European Commission (project 
INCA LSHC-CT-2005-018704), the "Fonds national de la recherche scien-
tifique" (FNRS) and the Télévie, the Belgian Foundation against Cancer, the 
Bekales Foundation, and the CGRI (Commissariat général des relations 
internationales). NG ("Télévie" Fellows), AF (Research Fellow), MB (FRIA 
Fellow), CB, HB and JD ("Télévie" Fellows) and RK and LW (Research 
Directors) are members of the FNRS. We also wish to thank our numerous 
collaborators who contributed to our previous research projects on BLV, 
and in particular during the last 5 year period: Becca Asquith, Charles Bang-
ham, Delphine Collete, Christophe Debacq, François Debande, Jack Hay, 
Geneviève Jean, Pierre Kerkhofs, Laurent Lefèbvre, Jean-Marie Londes, 
Charafa Merezak, Franck Mortreux, Daniel Portetelle, Maria Teresa 
Sanchez-Alcaraz, Isabelle Schwartz-Cornil, Jean-Claude Twizere, Patrice 
Urbain, Carine Van Lint and Eric Wattel.
References
1. Leisering A: .  Ber Vet -Wes Kgr Sachen 1871, 16:15.
2. Burny A, Cleuter Y, Kettmann R, Mammerickx M, Marbaix G, Porte-
telle D, Van den BA, Willems L, Thomas R: Bovine leukaemia: facts
and hypotheses derived from the study of an infectious can-
cer.  Cancer Surv 1987, 6:139-159.
3. Olson C, Miller J: .  Enzootic bovine leukosis and bovine leukemia virus
Martinus Nijhoff Publishing, Boston 1987:3.
4. Willems L, Burny A, Dangoisse O, Collete D, Dequiedt F, Gatot JS,
Kerkhofs P, Lefebvre L, Merezak C, Portetelle D, Twizere JC, Kett-
mann R: Bovine leukemia virus as a model for human T-cell
leukemia virus.  Current Topics in Virology 1999:139-167.
5. Meas S, Usui T, Ohashi K, Sugimoto C, Onuma M: Vertical transmis-
sion of bovine leukemia virus and bovine immunodeficiency
virus in dairy cattle herds.  Vet Microbiol 2002, 84:275-282.
6. Ferrer JF, Piper CE: An evaluation of the role of milk in the nat-
ural transmission of BLV.  Ann Rech Vet 1978, 9:803-807.
7. Hopkins SG, DiGiacomo RF: Natural transmission of bovine
leukemia virus in dairy and beef cattle.  Vet Clin North Am Food
Anim Pract 1997, 13:107-128.
8. Mammerickx M, Portetelle D, de Clercq K, Burny A: Experimental
transmission of enzootic bovine leukosis to cattle, sheep and
goats: infectious doses of blood and incubation period of the
disease.  Leuk Res 1987, 11:353-358.
9. Kohara J, Konnai S, Onuma M: Experimental transmission of
Bovine leukemia virus in cattle via rectal palpation.  Jpn J Vet
Res 2006, 54:25-30.
10. Brenner J, Rosenthal I, Bernstein S, Trainin Z: The fat content of
milk from dairy cattle infected with bovine leukosis virus.  Vet
Res Commun 1990, 14:167-171.
11. Da Y, Shanks RD, Stewart JA, Lewin HA: Milk and fat yields decline
in bovine leukemia virus-infected Holstein cattle with persist-
ent lymphocytosis.  Proc Natl Acad Sci U S A 1993, 90:6538-6541.
12. Huber NL, DiGiacomo RF, Evermann JF, Studer E: Bovine leukemia
virus infection in a large Holstein herd: prospective compari-
son of production and reproductive performance in antibody-
negative and antibody-positive cows.  Am J Vet Res 1981,
42:1477-1481.
13. Jacobs RM, Heeney JL, Godkin MA, Leslie KE, Taylor JA, Davies C, Valli
VE:  Production and related variables in bovine leukaemia
virus-infected cows.  Vet Res Commun 1991, 15:463-474.
14. Pollari FL, Wangsuphachart VL, DiGiacomo RF, Evermann JF: Effects
of bovine leukemia virus infection on production and repro-
duction in dairy cattle.  Can J Vet Res 1992, 56:289-295.
15. Wu MC, Shanks RD, Lewin HA: Milk and fat production in dairy
cattle influenced by advanced subclinical bovine leukemia
virus infection.  Proc Natl Acad Sci U S A 1989, 86:993-996.
16. Kurdi A, Blankenstein P, Marquardt O, Ebner D: Study on the pres-
ence of BLV infection in a dairy herd in Syria by using serolog-
ical and virological tests.  Berliner und Munchener Tierarztliche
Wochenschrift 1999, 112:18-23.
17. Motton DD, Buehring GC: Bovine leukemia virus alters growth
properties and casein synthesis in mammary epithelial cells.
J Dairy Sci 2003, 86:2826-2838.
18. Trono KG, Perez-Filgueira DM, Duffy S, Borca MV, Carrillo C: Sero-
prevalence of bovine leukemia virus in dairy cattle in Argen-
tina: comparison of sensitivity and specificity of different
detection methods.  Vet Microbiol 2001, 83:235-248.
19. Ott SL, Johnson R, Wells SJ: Association between bovine-leukosis
virus seroprevalence and herd-level productivity on US dairy
farms.  Prev Vet Med 2003, 61:249-262.
20. Rhodes JK, Pelzer KD, Johnson YJ: Economic implications of
bovine leukemia virus infection in mid-Atlantic dairy herds.  J
Am Vet Med Assoc 2003, 223:346-352.
21. Bendixen HJ: Epizootiology, diagnosis and control of bovine
leukosis.  Bull Off Int Epizoot 1967, 68:73-99.
22. Altanerova V, Holicova D, Kucerova L, Altaner C, Lairmore MD,
Boris-Lawrie K: Long-term infection with retroviral structural
gene vector provides protection against bovine leukemia
virus disease in rabbits.  Virology 2004, 329:434-439.
23. Bondzio A, Abraham-Podgornik A, Blankenstein P, Risse S: Involve-
ment of intracellular Ca2+ in the regulation of bovine leuke-
mia virus expression.  Biol Chem 2001, 382:407-416.
24. Camargos MF, Pereda A, Stancek D, Rocha MA, Reis JK, Greiser-
Wilke I, Leite RC: Molecular characterization of the env gene
from Brazilian field isolates of Bovine Leukemia Virus.  Virus
Genes 2006.
25. Ferens WA, Cobbold R, Hovde CJ: Intestinal Shiga toxin-produc-
ing Escherichia coli bacteria mitigate bovine leukemia virus
infection in experimentally infected sheep.  Infect Immun 2006,
74:2906-2916.
26. Kerkhofs P, Gatot JS, Knapen K, Mammerickx M, Burny A, Portetelle
D, Willems L, Kettmann R: Long-term protection against bovine
leukaemia virus replication in cattle and sheep.  J Gen Virol 2000,
81:957-963.
27. Murovska MF, Chernobayeva LG, Miroshnichenko OI, Tomsons VP,
Konicheva VV, Ivanova SV, Tikhonenko TI: An investigation of the
effect of antisense RNA gene on bovine leukaemia virus
reproduction in cell culture.  Vet Microbiol 1992, 33:361-366.
28. Kucerova L, Altanerova V, Altaner C, Boris-Lawrie K: Bovine leuke-
mia virus structural gene vectors are immunogenic and lack
pathogenicity in a rabbit model.  J Virol 1999, 73:8160-8166.
29. Okada K, Nakae N, Kuramochi K, Yin SA, Ikeda M, Takami S, Hirata
T, Goryo M, Numakunai S, Takeshima SN, Takahashi M, Tajima S, Kon-
nai S, Onuma M, Aida Y: Bovine leukemia virus high tax molecu-
lar clone experimentally induces leukemia/lymphoma in
sheep.  J Vet Med Sci 2005, 67:1231-1235.
30. Tana, Watarai S, Aida Y, Tajima S, Kakidani H, Onuma M, Kodama H:
Growth inhibition of cancer cells by co-transfection of diph-
theria toxin A-chain gene plasmid with bovine leukemia
virus-tax expression vector.  Microbiol Immunol 2001, 45:447-455.
31. Usui T, Konnai S, Tajima S, Watarai S, Aida Y, Ohashi K, Onuma M:
Protective effects of vaccination with bovine leukemia virus
(BLV) Tax DNA against BLV infection in sheep.  J Vet Med Sci
2003, 65:1201-1205.
32. Reichert M, Cantor GH, Willems L, Kettmann R: Protective effects
of a live attenuated bovine leukaemia virus vaccine with dele-
tion in the R3 and G4 genes.  J Gen Virol 2000, 81:965-969.
33. Rola M, Kuzmak J: The detection of bovine leukemia virus pro-
viral DNA by PCR-ELISA.  J Virol Methods 2002, 99:33-40.
34. Marin C, de Lopez NM, Alvarez L, Lozano O, Espana W, Castanos H,
Leon A: Epidemiology of bovine leukemia in Venezuela.  Ann
Rech Vet 1978, 9:743-746.
35. Meas S, Seto J, Sugimoto C, Bakhsh M, Riaz M, Sato T, Naeem K,
Ohashi K, Onuma M: Infection of bovine immunodeficiency
virus and bovine leukemia virus in water buffalo and cattle
populations in Pakistan.  J Vet Med Sci 2000, 62:329-331.
36. Singh CM, Singh B, Parihar NS: Pulmonary involvement in lym-
phosarcoma of Indian buffaloes.  Bibl Haematol 1973, 39:220-227.
37. Altanerova V, Ban J, Altaner C: Induction of immune deficiency
syndrome in rabbits by bovine leukaemia virus.  AIDS 1989,
3:755-758.
38. Onuma M, Wada M, Yasutomi Y, Yamamoto M, Okada HM, Kawakami
Y: Suppression of immunological responses in rabbits experi-
mentally infected with bovine leukemia virus.  Vet Microbiol
1990, 25:131-141.
39. Wyatt CR, Wingett D, White JS, Buck CD, Knowles D, Reeves R, Mag-
nuson NS: Persistent infection of rabbits with bovine leukemia
virus associated with development of immune dysfunction.  J
Virol 1989, 63:4498-4506.
40. Altanerova V, Portetelle D, Kettmann R, Altaner C: Infection of rats
with bovine leukaemia virus: establishment of a virus-produc-
ing rat cell line.  J Gen Virol 1989, 70 ( Pt 7):1929-1932.
41. Boris-Lawrie K, Altanerova V, Altaner C, Kucerova L, Temin HM: In
vivo study of genetically simplified bovine leukemia virus
derivatives that lack tax and rex.  J Virol 1997, 71:1514-1520.
42. Altanerova V, Ban J, Kettmann R, Altaner C: Induction of leukemia
in chicken by bovine leukemia virus due to insertional muta-
genesis.  Arch Geschwulstforsch 1990, 60:89-96.Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 25 of 32
(page number not for citation purposes)
43. Mammerickx M, Portetelle D, Burny A: Experimental cross-trans-
missions of bovine leukemia virus (BLV) between several ani-
mal species.  Zentralbl Veterinarmed B 1981, 28:69-81.
44. Olson C, Kettmann R, Burny A, Kaja R: Goat lymphosarcoma
from bovine leukemia virus.  J Natl Cancer Inst 1981, 67:671-675.
45. Djilali S, Parodi AL, Levy D, Cockerell GL: Development of leuke-
mia and lymphosarcoma induced by bovine leukemia virus in
sheep: a hematopathological study.  Leukemia 1987, 1:777-781.
46. Djilali S, Parodi AL: The BLV-induced leukemia--lymphosar-
coma complex in sheep.  Vet Immunol Immunopathol 1989,
22:233-244.
47. Mammerickx M, Palm R, Portetelle D, Burny A: Experimental trans-
mission of enzootic bovine leukosis to sheep: latency period
of the tumoral disease.  Leukemia 1988, 2:103-107.
48. Zhao TM, Hague B, Caudell DL, Simpson RM, Kindt TJ: Quantifica-
tion of HTLV-I proviral load in experimentally infected rab-
bits.  Retrovirology 2005, 2:34.
49. Derse D, Martarano L: Construction of a recombinant bovine
leukemia virus vector for analysis of virus infectivity.  J Virol
1990, 64:401-405.
50. Graves DC, Ferrer JF: In vitro transmission and propagation of
the bovine leukemia virus in monolayer cell cultures.  Cancer
Res 1976, 36:4152-4159.
51. Inabe K, Ikuta K, Aida Y: Transmission and propagation in cell
culture of virus produced by cells transfected with an infec-
tious molecular clone of bovine leukemia virus.  Virology 1998,
245:53-64.
52. Milan D, Nicolas JF: Activator-dependent and activator-inde-
pendent defective recombinant retroviruses from bovine
leukemia virus.  J Virol 1991, 65:1938-1945.
53. DiGiacomo RF, Hopkins SG: Food animal and poultry retrovi-
ruses and human health.  Vet Clin North Am Food Anim Pract 1997,
13:177-190.
54. Perzova RN, Loughran TP, Dube S, Ferrer J, Esteban E, Poiesz BJ: Lack
of BLV and PTLV DNA sequences in the majority of patients
with large granular lymphocyte leukaemia.  Br J Haematol 2000,
109:64-70.
55. Burmeister T, Schwartz S, Hummel M, Hoelzer D, Thiel E: No
genetic evidence for involvement of Deltaretroviruses in
adult patients with precursor and mature T-cell neoplasms.
Retrovirology 2007, 4:11.
56. Buehring GC, Philpott SM, Choi KY: Humans have antibodies
reactive with Bovine leukemia virus.  AIDS Res Hum Retroviruses
2003, 19:1105-1113.
57. Calattini S, Chevalier SA, Duprez R, Afonso P, Froment A, Gessain A,
Mahieux R: Human T-cell lymphotropic virus type 3: complete
nucleotide sequence and characterization of the human tax3
protein.  J Virol 2006, 80:9876-9888.
58. Mahieux R, Gessain A: [New human retroviruses: HTLV-3 and
HTLV-4].  Med Trop (Mars ) 2005, 65:525-528.
59. Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe
U, Torimiro JN, Prosser AT, Lebreton M, Mpoudi-Ngole E,
McCutchan FE, Birx DL, Folks TM, Burke DS, Switzer WM: Emer-
gence of unique primate T-lymphotropic viruses among cen-
tral African bushmeat hunters.  Proc Natl Acad Sci U S A 2005,
102:7994-7999.
60. Rice NR, Stephens RM, Couez D, Deschamps J, Kettmann R, Burny A,
Gilden RV: The nucleotide sequence of the env gene and post-
env region of bovine leukemia virus.  Virology 1984, 138:82-93.
61. Sagata N, Yasunaga T, Ohishi K, Tsuzuku-Kawamura J, Onuma M,
Ikawa Y: Comparison of the entire genomes of bovine leuke-
mia virus and human T-cell leukemia virus and characteriza-
tion of their unidentified open reading frames.  EMBO J 1984,
3:3231-3237.
62. Sagata N, Yasunaga T, Ogawa Y, Tsuzuku-Kawamura J, Ikawa Y:
Bovine leukemia virus: unique structural features of its long
terminal repeats and its evolutionary relationship to human
T-cell leukemia virus.  Proc Natl Acad Sci U S A 1984, 81:4741-4745.
63. Dube S, Bachman S, Spicer T, Love J, Choi D, Esteban E, Ferrer JF, Poi-
esz BJ: Degenerate and specific PCR assays for the detection
of bovine leukaemia virus and primate T cell leukaemia/lym-
phoma virus pol DNA and RNA: phylogenetic comparisons of
amplified sequences from cattle and primates from around
the world.  J Gen Virol 1997, 78 ( Pt 6):1389-1398.
64. Mamoun RZ, Morisson M, Rebeyrotte N, Busetta B, Couez D, Kett-
mann R, Hospital M, Guillemain B: Sequence variability of bovine
leukemia virus env gene and its relevance to the structure
and antigenicity of the glycoproteins.  J Virol 1990, 64:4180-4188.
65. Licursi M, Inoshima Y, Wu D, Yokoyama T, Gonzalez ET, Sentsui H:
Provirus variants of bovine leukemia virus in naturally
infected cattle from Argentina and Japan.  Vet Microbiol 2003,
96:17-23.
66. Monti G, Schrijver R, Beier D: Genetic diversity and spread of
Bovine leukaemia virus isolates in Argentine dairy cattle.  Arch
Virol 2005, 150:443-458.
67. Ferrer JF, Stock ND, Lin P: Detection of replicating C-type
viruses in continuous cell cultures established from cows with
leukemia: effect of the culture medium.  J Natl Cancer Inst 1971,
47:613-621.
68. Miller JM, Miller LD, Olson C, Gillette KG: Virus-like particles in
phytohemagglutinin-stimulated lymphocyte cultures with
reference to bovine lymphosarcoma.  J Natl Cancer Inst 1969,
43:1297-1305.
69. Ghysdael J, Kettmann R, Burny A: Translation of bovine leukemia
virus virion RNAs in heterologous protein-synthesizing sys-
tems.  J Virol 1979, 29:1087-1098.
70. Katoh I, Kyushiki H, Sakamoto Y, Ikawa Y, Yoshinaka Y: Bovine
leukemia virus matrix-associated protein MA(p15): further
processing and formation of a specific complex with the
dimer of the 5'-terminal genomic RNA fragment.  J Virol 1991,
65:6845-6855.
71. Katoh I, Yasunaga T, Yoshinaka Y: Bovine leukemia virus RNA
sequences involved in dimerization and specific gag protein
binding: close relation to the packaging sites of avian, murine,
and human retroviruses.  J Virol 1993, 67:1830-1839.
72. Mansky LM, Krueger AE, Temin HM: The bovine leukemia virus
encapsidation signal is discontinuous and extends into the 5'
end of the gag gene.  J Virol 1995, 69:3282-3289.
73. Kurg A, Sommer G, Metspalu A: An RNA stem-loop structure
involved in the packaging of bovine leukemia virus genomic
RNA in vivo.  Virology 1995, 211:434-442.
74. Mansky LM, Wisniewski RM: The bovine leukemia virus encapsi-
dation signal is composed of RNA secondary structures.  J Virol
1998, 72:3196-3204.
75. Mansky LM, Gajary LC: The primary nucleotide sequence of the
bovine leukemia virus RNA packaging signal can influence
efficient RNA packaging and virus replication.  Virology 2002,
301:272-280.
76. Jewell NA, Mansky LM: Packaging of heterologous RNAs by a
minimal bovine leukemia virus RNA packaging signal into
virus particles.  Arch Virol 2005, 150:1161-1173.
77. Wang H, Norris KM, Mansky LM: Involvement of the matrix and
nucleocapsid domains of the bovine leukemia virus Gag poly-
protein precursor in viral RNA packaging.  J Virol 2003,
77:9431-9438.
78. Alexandersen S, Carpenter S, Christensen J, Storgaard T, Viuff B, Wan-
nemuehler Y, Belousov J, Roth JA: Identification of alternatively
spliced mRNAs encoding potential new regulatory proteins in
cattle infected with bovine leukemia virus.  J Virol 1993,
67:39-52.
79. Mamoun RZ, Astier-Gin T, Kettmann R, Deschamps J, Rebeyrotte N,
Guillemain BJ: The pX region of the bovine leukemia virus is
transcribed as a 2.1-kilobase mRNA.  J Virol 1985, 54:625-629.
80. Derse D, Casey JW: Two elements in the bovine leukemia virus
long terminal repeat that regulate gene expression.  Science
1986, 231:1437-1440.
81. Katoh I, Yoshinaka Y, Ikawa Y: Bovine leukemia virus trans-acti-
vator p38tax activates heterologous promoters with a com-
mon sequence known as a cAMP-responsive element or the
binding site of a cellular transcription factor ATF.  EMBO J
1989, 8:497-503.
82. Willems L, Kettmann R, Dequiedt F, Portetelle D, Voneche V, Cornil
I, Kerkhofs P, Burny A, Mammerickx M: In vivo infection of sheep
by bovine leukemia virus mutants.  J Virol 1993, 67:4078-4085.
83. Adam E, Kerkhofs P, Mammerickx M, Kettmann R, Burny A, Droog-
mans L, Willems L: Involvement of the cyclic AMP-responsive
element binding protein in bovine leukemia virus expression
in vivo.  J Virol 1994, 68:5845-5853.
84. Adam E, Kerkhofs P, Mammerickx M, Burny A, Kettman R, Willems L:
The CREB, ATF-1, and ATF-2 transcription factors from
bovine leukemia virus-infected B lymphocytes activate viral
expression.  J Virol 1996, 70:1990-1999.
85. Boros IM, Tie F, Giam CZ: Interaction of bovine leukemia virus
transactivator Tax with bZip proteins.  Virology 1995,
214:207-214.
86. Yin MJ, Gaynor RB: Complex formation between CREB and Tax
enhances the binding affinity of CREB for the human T-cell
leukemia virus type 1 21-base-pair repeats.  Mol Cell Biol 1996,
16:3156-3168.
87. Merezak C, Pierreux C, Adam E, Lemaigre F, Rousseau GG, Calomme
C, Van Lint C, Christophe D, Kerkhofs P, Burny A, Kettmann R, Wil-
lems L: Suboptimal enhancer sequences are required for effi-
cient bovine leukemia virus propagation in vivo: implications
for viral latency.  J Virol 2001, 75:6977-6988.Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 26 of 32
(page number not for citation purposes)
88. Calomme C, Dekoninck A, Nizet S, Adam E, Nguyen TL, Van den BA,
Willems L, Kettmann R, Burny A, Van Lint C: Overlapping CRE and
E box motifs in the enhancer sequences of the bovine leuke-
mia virus 5' long terminal repeat are critical for basal and
acetylation-dependent transcriptional activity of the viral
promoter: implications for viral latency.  J Virol 2004,
78:13848-13864.
89. Brooks PA, Nyborg JK, Cockerell GL: Identification of an NF-
kappa B binding site in the bovine leukemia virus promoter.
J Virol 1995, 69:6005-6009.
90. Brooks PA, Cockerell GL, Nyborg JK: Activation of BLV transcrip-
tion by NF-kappa B and Tax.  Virology 1998, 243:94-98.
91. Niermann GL, Buehring GC: Hormone regulation of bovine
leukemia virus via the long terminal repeat.  Virology 1997,
239:249-258.
92. Xiao J, Buehring GC: In vivo protein binding and functional anal-
ysis of cis-acting elements in the U3 region of the bovine
leukemia virus long terminal repeat.  J Virol 1998, 72:5994-6003.
93. Dekoninck A, Calomme C, Nizet S, de Launoit Y, Burny A, Ghysdael
J, Van Lint C: Identification and characterization of a PU.1/Spi-
B binding site in the bovine leukemia virus long terminal
repeat.  Oncogene 2003, 22:2882-2896.
94. Calomme C, Nguyen TL, de Launoit Y, Kiermer V, Droogmans L,
Burny A, Van Lint C: Upstream stimulatory factors binding to an
E box motif in the R region of the bovine leukemia virus long
terminal repeat stimulates viral gene expression.  J Biol Chem
2002, 277:8775-8789.
95. Kiermer V, Van Lint C, Briclet D, Vanhulle C, Kettmann R, Verdin E,
Burny A, Droogmans L: An interferon regulatory factor binding
site in the U5 region of the bovine leukemia virus long termi-
nal repeat stimulates Tax-independent gene expression.  J
Virol 1998, 72:5526-5534.
96. Merezak C, Reichert M, Van Lint C, Kerkhofs P, Portetelle D, Willems
L, Kettmann R: Inhibition of histone deacetylases induces
bovine leukemia virus expression in vitro and in vivo.  J Virol
2002, 76:5034-5042.
97. Nguyen TL, Calomme C, Wijmeersch G, Nizet S, Veithen E, Portetelle
D, de Launoit Y, Burny A, Van Lint C: Deacetylase inhibitors and
the viral transactivator TaxBLV synergistically activate
bovine leukemia virus gene expression via a cAMP-responsive
element- and cAMP-responsive element-binding protein-
dependent mechanism.  J Biol Chem 2004, 279:35025-35036.
98. Tajima S, Tsukamoto M, Aida Y: Latency of viral expression in vivo
is not related to CpG methylation in the U3 region and part
of the R region of the long terminal repeat of bovine leukemia
virus.  J Virol 2003, 77:4423-4430.
99. Taniguchi Y, Nosaka K, Yasunaga J, Maeda M, Mueller N, Okayama A,
Matsuoka M: Silencing of human T-cell leukemia virus type I
gene transcription by epigenetic mechanisms.  Retrovirology
2005, 2:64.
100. Derse D: trans-acting regulation of bovine leukemia virus
mRNA processing.  J Virol 1988, 62:1115-1119.
101. Deshayes L, Levy D, Parodi AL, Levy JP: Proteins of bovine leuke-
mia virus. I. Characterization and reactions with natural anti-
bodies.  J Virol 1977, 21:1056-1060.
102. Gupta P, Ferrer JF: Detection of a precursor-like protein of
bovine leukaemia virus structural polypeptides in purified vir-
ions.  J Gen Virol 1980, 47:311-322.
103. Mamoun RZ, Astier T, Guillemain B, Duplan JF: Bovine lymphosar-
coma: expression of BLV-related proteins in cultured cells.  J
Gen Virol 1983, 64 (Pt 9):1895-1905.
104. Oroszlan S, Copeland TD, Henderson LE, Stephenson JR, Gilden RV:
Amino-terminal sequence of bovine leukemia virus major
internal protein: homology with mammalian type C virus p30
structural proteins.  Proc Natl Acad Sci U S A 1979, 76:2996-3000.
105. Uckert W, Grofova M, Beaudreau G: Translational order of
bovine leukemia virus gag and env gene-coded proteins.  Virol-
ogy 1984, 135:288-292.
106. Matthews S, Mikhailov M, Burny A, Roy P: The solution structure
of the bovine leukaemia virus matrix protein and similarity
with lentiviral matrix proteins.  EMBO J 1996, 15:3267-3274.
107. Copeland TD, Morgan MA, Oroszlan S: Complete amino acid
sequence of the nucleic acid-binding protein of bovine leuke-
mia virus.  FEBS Lett 1983, 156:37-40.
108. Morcock DR, Katakam S, Kane BP, Casas-Finet JR: Fluorescence and
nucleic acid binding properties of bovine leukemia virus
nucleocapsid protein.  Biophys Chem 2002, 97:203-212.
109. Gilden RV, Long CW, Hanson M, Toni R, Charman HP, Oroszlan S,
Miller JM, Van der Maaten MJ: Characteristics of the major inter-
nal protein and RNA-dependent DNA polymerase of bovine
leukaemia virus.  J Gen Virol 1975, 29:305-314.
110. Mager A, Masengo R, Mammerickx M, Letesson JJ: T cell prolifera-
tive response to bovine leukaemia virus (BLV): identification
of T cell epitopes on the major core protein (p24) in BLV-
infected cattle with normal haematological values.  J Gen Virol
1994, 75 ( Pt 9):2223-2231.
111. Willems L, Kerkhofs P, Attenelle L, Burny A, Portetelle D, Kettmann
R:  The major homology region of bovine leukaemia virus
p24gag is required for virus infectivity in vivo.  J Gen Virol 1997,
78 ( Pt 3):637-640.
112. Onuma M, Tsukiyama K, Ohya K, Morishima Y, Ohno R: Detection
of cross-reactive antibody to BLV p24 in sera of human
patients infected with HTLV.  Microbiol Immunol 1987, 31:131-137.
113. Zandomeni RO, Carrera-Zandomeni M, Esteban E, Ferrer JF: The
trans-activating C-type retroviruses share a distinct
epitope(s) that induces antibodies in certain infected hosts.  J
Gen Virol 1991, 72 ( Pt 9):2113-2119.
114. Morgan MA, Copeland TD, Oroszlan S: Structural and antigenic
analysis of the nucleic acid-binding proteins of bovine and
feline leukemia viruses.  J Virol 1983, 46:177-186.
115. Yoshinaka Y, Katoh I, Copeland TD, Smythers GW, Oroszlan S:
Bovine leukemia virus protease: purification, chemical analy-
sis, and in vitro processing of gag precursor polyproteins.  J
Virol 1986, 57:826-832.
116. Llames L, Goyache J, Domenech A, Montana AV, Suarez G, Gomez-
Lucia E: Cellular distribution of bovine leukemia virus proteins
gp51SU, Pr72(env), and Pr66(gag-pro) in persistently
infected cells.  Virus Res 2001, 79:47-57.
117. Katoh I, Yasunaga T, Ikawa Y, Yoshinaka Y: Inhibition of retroviral
protease activity by an aspartyl proteinase inhibitor.  Nature
1987, 329:654-656.
118. Zahuczky G, Boross P, Bagossi P, Emri G, Copeland TD, Oroszlan S,
Louis JM, Tozser J: Cloning of the bovine leukemia virus protei-
nase in Escherichia coli and comparison of its specificity to
that of human T-cell leukemia virus proteinase.  Biochim Biophys
Acta 2000, 1478:1-8.
119. Wang H, Norris KM, Mansky LM: Analysis of bovine leukemia
virus gag membrane targeting and late domain function.  J
Virol 2002, 76:8485-8493.
120. Wang H, Machesky NJ, Mansky LM: Both the PPPY and PTAP
motifs are involved in human T-cell leukemia virus type 1 par-
ticle release.  J Virol 2004, 78:1503-1512.
121. Callahan R, Lieber MM, Todaro GJ, Graves DC, Ferrer JF: Bovine
leukemia virus genes in the DNA of leukemic cattle.  Science
1976, 192:1005-1007.
122. Kettmann R, Portetelle D, Mammerickx M, Cleuter Y, Dekegel D,
Galoux M, Ghysdael J, Burny A, Chantrenne H: Bovine leukemia
virus: an exogenous RNA oncogenic virus.  Proc Natl Acad Sci U
S A 1976, 73:1014-1018.
123. Avidan O, Meer ME, Oz I, Hizi A: The processivity and fidelity of
DNA synthesis exhibited by the reverse transcriptase of
bovine leukemia virus.  Eur J Biochem 2002, 269:859-867.
124. Perach M, Hizi A: Catalytic features of the recombinant reverse
transcriptase of bovine leukemia virus expressed in bacteria.
Virology 1999, 259:176-189.
125. Mansky LM, Temin HM: Lower mutation rate of bovine leukemia
virus relative to that of spleen necrosis virus.  J Virol 1994,
68:494-499.
126. Kashmiri SV, Mehdi R, Ferrer JF: Molecular cloning of covalently
closed circular DNA of bovine leukemia virus.  J Virol 1984,
49:583-587.
127. Kettmann R, Couez D, Burny A: Restriction endonuclease map-
ping of linear unintegrated proviral DNA of bovine leukemia
virus.  J Virol 1981, 38:27-33.
128. Reyes RA, Cockerell GL: Unintegrated bovine leukemia virus
DNA: association with viral expression and disease.  J Virol
1996, 70:4961-4965.
129. Tanaka AS, Tanaka M, Komuro K: A highly efficient method for
the site-specific integration of transfected plasmids into the
genome of mammalian cells using purified retroviral inte-
grase.  Gene 1998, 216:67-76.
130. Tanaka AS, Komuro K: Targeted rearrangement of a chromo-
somal repeat sequence by transfection of a homologous DNA
sequence using purified integrase.  Gene Ther 2005, 12:783-794.
131. Derse D, Diniak AJ, Casey JW, Deininger PL: Nucleotide sequence
and structure of integrated bovine leukemia virus long termi-
nal repeats.  Virology 1985, 141:162-166.
132. Coulston J, Naif H, Brandon R, Kumar S, Khan S, Daniel RC, Lavin MF:
Molecular cloning and sequencing of an Australian isolate of
proviral bovine leukaemia virus DNA: comparison with other
isolates.  J Gen Virol 1990, 71 ( Pt 8):1737-1746.
133. Rice NR, Stephens RM, Gilden RV: Sequence analysis of the
bovine leukemia virus genome.  Enzootic bovine leukosis and bovineRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 27 of 32
(page number not for citation purposes)
leukemia virus Martinus Nijhoff Publishing, The Hague, The Netherlands
1987:115-144.
134. Deshayes L, Levy D, Parodi AL, Levy JP: Spontaneous immune
response of bovine leukemia-virus-infected cattle against five
different viral proteins.  Int J Cancer 1980, 25:503-508.
135. Zarkik S, Decroly E, Wattiez R, Seidah NG, Burny A, Ruysschaert JM:
Comparative processing of bovine leukemia virus envelope
glycoprotein gp72 by subtilisin/kexin-like mammalian conver-
tases.  FEBS Lett 1997, 406:205-210.
136. Bruck C, Rensonnet N, Portetelle D, Cleuter Y, Mammerickx M,
Burny A, Mamoun R, Guillemain B, Van der Maaten MJ, Ghysdael J:
Biologically active epitopes of bovine leukemia virus glyco-
protein gp51: their dependence on protein glycosylation and
genetic variability.  Virology 1984, 136:20-31.
137. Phillips M, Miller JM, Van der Maaten MJ: Isolation of a precipitating
glycoprotein antigen from cell cultures persistently infected
with bovine leukemia virus.  J Natl Cancer Inst 1978, 60:213-217.
138. Portetelle D, Bruck C, Mammerickx M, Burny A: In animals infected
by bovine leukemia virus (BLV) antibodies to envelope glyco-
protein gp51 are directed against the carbohydrate moiety.
Virology 1980, 105:223-233.
139. Schultz AM, Copeland TD, Oroszlan S: The envelope proteins of
bovine leukemia virus: purification and sequence analysis.
Virology 1984, 135:417-427.
140. Johnston ER, Radke K: The SU and TM envelope protein subu-
nits of bovine leukemia virus are linked by disulfide bonds,
both in cells and in virions.  J Virol 2000, 74:2930-2935.
141. Bruck C, Mathot S, Portetelle D, Berte C, Franssen JD, Herion P,
Burny A: Monoclonal antibodies define eight independent anti-
genic regions on the bovine leukemia virus (BLV) envelope
glycoprotein gp51.  Virology 1982, 122:342-352.
142. Callebaut I, Mornon JP, Burny A, Portetelle D: The bovine leukemia
virus (BLV) envelope glycoprotein gp51 as a general model
for the design of a subunit vaccine against retroviral infection:
mapping of functional sites through immunological and struc-
tural data.  Leukemia 1994, 8 Suppl 1:S218-S221.
143. Callebaut I, Voneche V, Mager A, Fumiere O, Krchnak V, Merza M,
Zavada J, Mammerickx M, Burny A, Portetelle D: Mapping of B-neu-
tralizing and T-helper cell epitopes on the bovine leukemia
virus external glycoprotein gp51.  J Virol 1993, 67:5321-5327.
144. Portetelle D, Dandoy C, Burny A, Zavada J, Siakkou H, Gras-Masse H,
Drobecq H, Tartar A: Synthetic peptides approach to identifica-
tion of epitopes on bovine leukemia virus envelope glycopro-
tein gp51.  Virology 1989, 169:34-41.
145. Gatei MH, Good MF, Daniel RC, Lavin MF: T-cell responses to
highly conserved CD4 and CD8 epitopes on the outer mem-
brane protein of bovine leukemia virus: relevance to vaccine
development.  J Virol 1993, 67:1796-1802.
146. Hislop AD, Good MF, Mateo L, Gardner J, Gatei MH, Daniel RC, Mey-
ers BV, Lavin MF, Suhrbier A: Vaccine-induced cytotoxic T lym-
phocytes protect against retroviral challenge.  Nat Med 1998,
4:1193-1196.
147. Mateo L, Gardner J, Suhrbier A: Delayed emergence of bovine
leukemia virus after vaccination with a protective cytotoxic T
cell-based vaccine.  AIDS Res Hum Retroviruses 2001, 17:1447-1453.
148. Johnston ER, Albritton LM, Radke K: Envelope proteins containing
single amino acid substitutions support a structural model of
the receptor-binding domain of bovine leukemia virus surface
protein.  J Virol 2002, 76:10861-10872.
149. Ghez D, Lepelletier Y, Lambert S, Fourneau JM, Blot V, Janvier S,
Arnulf B, van Endert PM, Heveker N, Pique C, Hermine O: Neuropi-
lin-1 is involved in human T-cell lymphotropic virus type 1
entry.  J Virol 2006, 80:6844-6854.
150. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL: The ubiqui-
tous glucose transporter GLUT-1 is a receptor for HTLV.  Cell
2003, 115:449-459.
151. Ban J, Portetelle D, Altaner C, Horion B, Milan D, Krchnak V, Burny A,
Kettmann R: Isolation and characterization of a 2.3-kilobase-
pair cDNA fragment encoding the binding domain of the
bovine leukemia virus cell receptor.  J Virol 1993, 67:1050-1057.
152. Suzuki T, Matsubara Y, Kitani H, Ikeda H: Evaluation of the delta
subunit of bovine adaptor protein complex 3 as a receptor for
bovine leukaemia virus.  J Gen Virol 2003, 84:1309-1316.
153. Gatot JS, Callebaut I, Mornon JP, Portetelle D, Burny A, Kerkhofs P,
Kettmann R, Willems L: Conservative mutations in the immuno-
suppressive region of the bovine leukemia virus transmem-
brane protein affect fusion but not infectivity in vivo.  J Biol
Chem 1998, 273:12870-12880.
154. Johnston ER, Powers MA, Kidd LC, Radke K: Peripheral blood
mononuclear cells from sheep infected with a variant of
bovine leukemia virus synthesize envelope glycoproteins but
fail to induce syncytia in culture.  J Virol 1996, 70:6296-6303.
155. Voneche V, Portetelle D, Kettmann R, Willems L, Limbach K, Paoletti
E, Ruysschaert JM, Burny A, Brasseur R: Fusogenic segments of
bovine leukemia virus and simian immunodeficiency virus are
interchangeable and mediate fusion by means of oblique
insertion in the lipid bilayer of their target cells.  Proc Natl Acad
Sci U S A 1992, 89:3810-3814.
156. Voneche V, Callebaut I, Kettmann R, Brasseur R, Burny A, Portetelle
D:  The 19-27 amino acid segment of gp51 adopts an
amphiphilic structure and plays a key role in the fusion events
induced by bovine leukemia virus.  J Biol Chem 1992,
267:15193-15197.
157. Gatot JS, Callebaut I, Van Lint C, Demonte D, Kerkhofs P, Portetelle
D, Burny A, Willems L, Kettmann R: Bovine leukemia virus SU
protein interacts with zinc, and mutations within two inter-
acting regions differently affect viral fusion and infectivity in
vivo.  J Virol 2002, 76:7956-7967.
158. Alber G, Kim KM, Weiser P, Riesterer C, Carsetti R, Reth M: Molec-
ular mimicry of the antigen receptor signalling motif by trans-
membrane proteins of the Epstein-Barr virus and the bovine
leukaemia virus.  Curr Biol 1993, 3:333-339.
159. Beaufils P, Choquet D, Mamoun RZ, Malissen B: The (YXXL/I)2 sig-
nalling motif found in the cytoplasmic segments of the bovine
leukaemia virus envelope protein and Epstein-Barr virus
latent membrane protein 2A can elicit early and late lym-
phocyte activation events.  EMBO J 1993, 12:5105-5112.
160. Inabe K, Nishizawa M, Tajima S, Ikuta K, Aida Y: The YXXL
sequences of a transmembrane protein of bovine leukemia
virus are required for viral entry and incorporation of viral
envelope protein into virions.  J Virol 1999, 73:1293-1301.
161. Willems L, Gatot JS, Mammerickx M, Portetelle D, Burny A, Kerkhofs
P, Kettmann R: The YXXL signalling motifs of the bovine leuke-
mia virus transmembrane protein are required for in vivo
infection and maintenance of high viral loads.  J Virol 1995,
69:4137-4141.
162. Grange MP, Blot V, Delamarre L, Bouchaert I, Rocca A, Dautry-Varsat
A, Dokhelar MC: Identification of two intracellular mechanisms
leading to reduced expression of oncoretrovirus envelope
glycoproteins at the cell surface.  J Virol 2000, 74:11734-11743.
163. Novakovic S, Sawai ET, Radke K: Dileucine and YXXL motifs in
the cytoplasmic tail of the bovine leukemia virus transmem-
brane envelope protein affect protein expression on the cell
surface.  J Virol 2004, 78:8301-8311.
164. Hamilton VT, Stone DM, Pritchard SM, Cantor GH: Bovine leuke-
mia virus gp30 transmembrane (TM) protein is not tyrosine
phosphorylated: examining potential interactions with host
tyrosine-mediated signaling.  Virus Res 2002, 90:155-169.
165. Reichert M, Winnicka A, Willems L, Kettmann R, Cantor GH: Role of
the proline-rich motif of bovine leukemia virus transmem-
brane protein gp30 in viral load and pathogenicity in sheep.  J
Virol 2001, 75:8082-8089.
166. Cantor GH, Pritchard SM, Orlik O, Splitter GA, Davis WC, Reeves R:
Bovine leukemia virus transmembrane protein gp30 physi-
cally associates with the down-regulatory phosphatase SHP-
1.  Cell Immunol 1999, 193:117-124.
167. Ciminale V, Pavlakis GN, Derse D, Cunningham CP, Felber BK: Com-
plex splicing in the human T-cell leukemia virus (HTLV) fam-
ily of retroviruses: novel mRNAs and proteins produced by
HTLV type I.  J Virol 1992, 66:1737-1745.
168. Lefebvre L, Ciminale V, Vanderplasschen A, D'Agostino D, Burny A,
Willems L, Kettmann R: Subcellular localization of the bovine
leukemia virus R3 and G4 accessory proteins.  J Virol 2002,
76:7843-7854.
169. Kerkhofs P, Heremans H, Burny A, Kettmann R, Willems L: In vitro
and in vivo oncogenic potential of bovine leukemia virus G4
protein.  J Virol 1998, 72:2554-2559.
170. Lefebvre L, Vanderplasschen A, Ciminale V, Heremans H, Dangoisse
O, Jauniaux JC, Toussaint JF, Zelnik V, Burny A, Kettmann R, Willems
L:  Oncoviral bovine leukemia virus G4 and human T-cell
leukemia virus type 1 p13(II) accessory proteins interact with
farnesyl pyrophosphate synthetase.  Journal of Virology 2002,
76:1400-1414.
171. Willems L, Kerkhofs P, Dequiedt F, Portetelle D, Mammerickx M,
Burny A, Kettmann R: Attenuation of bovine leukemia virus by
deletion of R3 and G4 open reading frames.  Proc Natl Acad Sci U
S A 1994, 91:11532-11536.
172. Powers MA, Grossman D, Kidd LC, Radke K: Episodic occurrence
of antibodies against the bovine leukemia virus Rex protein
during the course of infection in sheep.  J Virol 1991,
65:4959-4965.
173. Rice NR, Simek SL, Dubois GC, Showalter SD, Gilden RV, Stephens
RM: Expression of the bovine leukemia virus X region in virus-
infected cells.  J Virol 1987, 61:1577-1585.Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 28 of 32
(page number not for citation purposes)
174. McGirr KM, Buehring GC: tax and rex Sequences of bovine leu-
kaemia virus from globally diverse isolates: rex amino acid
sequence more variable than tax.  J Vet Med B Infect Dis Vet Public
Health 2005, 52:8-16.
175. Choi EA, Hope TJ: Mutational analysis of bovine leukemia virus
Rex: identification of a dominant-negative inhibitor.  J Virol
2005, 79:7172-7181.
176. Felber BK, Derse D, Athanassopoulos A, Campbell M, Pavlakis GN:
Cross-activation of the Rex proteins of HTLV-I and BLV and
of the Rev protein of HIV-1 and nonreciprocal interactions
with their RNA responsive elements.  New Biol 1989, 1:318-328.
177. Sagata N, Tsuzuku-Kawamura J, Nagayoshi-Aida M, Shimizu F, Imagawa
K, Ikawa Y: Identification and some biochemical properties of
the major XBL gene product of bovine leukemia virus.  Proc
Natl Acad Sci U S A 1985, 82:7879-7883.
178. Powers MA, Radke K: Activation of bovine leukemia virus tran-
scription in lymphocytes from infected sheep: rapid transition
through early to late gene expression.  J Virol 1992,
66:4769-4777.
179. Haas L, Divers T, Casey JW: Bovine leukemia virus gene expres-
sion in vivo.  J Virol 1992, 66:6223-6225.
180. Willems L, Bruck C, Portetelle D, Burny A, Kettmann R: Expression
of a cDNA clone corresponding to the long open reading
frame (XBL-I) of the bovine leukemia virus.  Virology 1987,
160:55-59.
181. Sakakibara N, Kabeya H, Ohashi K, Sugimoto C, Onuma M: Epitope
mapping of bovine leukemia virus transactivator protein tax.
J Vet Med Sci 1998, 60:599-605.
182. Ogawa Y, Sagata N, Tsuzuku-Kawamura J, Koyama H, Onuma M, Izawa
H, Ikawa Y: Structure of a defective provirus of bovine leuke-
mia virus.  Microbiol Immunol 1987, 31:1009-1015.
183. Van den BA, Cleuter Y, Chen G, Portetelle D, Mammerickx M, Zagury
D, Fouchard M, Coulombel L, Kettmann R, Burny A: Even transcrip-
tionally competent proviruses are silent in bovine leukemia
virus-induced sheep tumor cells.  Proc Natl Acad Sci U S A 1988,
85:9263-9267.
184. Tajima S, Ikawa Y, Aida Y: Complete bovine leukemia virus
(BLV) provirus is conserved in BLV-infected cattle through-
out the course of B-cell lymphosarcoma development.  J Virol
1998, 72:7569-7576.
185. Van den BA, Bagnis C, Ciesiolka M, Cleuter Y, Gelderblom H,
Kerkhofs P, Griebel P, Mannoni P, Burny A: In vivo rescue of a silent
tax-deficient bovine leukemia virus from a tumor-derived
ovine B-cell line by recombination with a retrovirally trans-
duced wild-type tax gene.  J Virol 1999, 73:1054-1065.
186. Twizere JC, Kruys V, Lefebvre L, Vanderplasschen A, Collete D,
Debacq C, Lai WS, Jauniaux JC, Bernstein LR, Semmes OJ, Burny A,
Blackshear PJ, Kettmann R, Willems L: Interaction of retroviral
Tax oncoproteins with tristetraprolin and regulation of
tumor necrosis factor-alpha expression.  J Natl Cancer Inst 2003,
95:1846-1859.
187. Willems L, Kettmann R, Burny A: The amino acid (157-197) pep-
tide segment of bovine leukemia virus p34tax encompass a
leucine-rich globally neutral activation domain.  Oncogene 1991,
6:159-163.
188. Chen G, Willems L, Portetelle D, Willard-Gallo KE, Burny A, Gheysen
D, Kettmann R: Synthesis of functional bovine leukemia virus
(BLV) p34tax protein by recombinant baculoviruses.  Virology
1989, 173:343-347.
189. Derse D: Bovine leukemia virus transcription is controlled by
a virus-encoded trans-acting factor and by cis-acting response
elements.  J Virol 1987, 61:2462-2471.
190. Willems L, Gegonne A, Chen G, Burny A, Kettmann R, Ghysdael J:
The bovine leukemia virus p34 is a transactivator protein.
EMBO J 1987, 6:3385-3389.
191. Sakurai M, Taneda A, Nagoya H, Sekikawa K: Construction and
functional characterization of mutants of the bovine leukae-
mia virus trans-activator protein p34tax.  J Gen Virol 1991, 72 (
Pt 10):2527-2531.
192. Willems L, Chen G, Portetelle D, Mamoun R, Burny A, Kettmann R:
Structural and functional characterization of mutants of the
bovine leukemia virus transactivator protein p34.  Virology
1989, 171:615-618.
193. Willems L, Grimonpont C, Heremans H, Rebeyrotte N, Chen G, Por-
tetelle D, Burny A, Kettmann R: Mutations in the bovine leukemia
virus Tax protein can abrogate the long terminal repeat-
directed transactivating activity without concomitant loss of
transforming potential.  Proc Natl Acad Sci U S A 1992,
89:3957-3961.
194. Tajima S, Aida Y: The region between amino acids 245 and 265
of the bovine leukemia virus (BLV) tax protein restricts trans-
activation not only via the BLV enhancer but also via other
retrovirus enhancers.  J Virol 2000, 74:10939-10949.
195. Tajima S, Aida Y: Mutant tax protein from bovine leukemia
virus with enhanced ability to activate the expression of c-fos.
J Virol 2002, 76:2557-2562.
196. Tajima S, Takahashi M, Takeshima SN, Konnai S, Yin SA, Watarai S,
Tanaka Y, Onuma M, Okada K, Aida Y: A mutant form of the tax
protein of bovine leukemia virus (BLV), with enhanced trans-
activation activity, increases expression and propagation of
BLV in vitro but not in vivo.  J Virol 2003, 77:1894-1903.
197. Takahashi M, Tajima S, Okada K, Davis WC, Aida Y: Involvement of
bovine leukemia virus in induction and inhibition of apoptosis.
Microbes Infect 2005, 7:19-28.
198. Willems L, Heremans H, Chen G, Portetelle D, Billiau A, Burny A,
Kettmann R: Cooperation between bovine leukaemia virus
transactivator protein and Ha-ras oncogene product in cellu-
lar transformation.  EMBO J 1990, 9:1577-1581.
199. Willems L, Grimonpont C, Kerkhofs P, Capiau C, Gheysen D, Conrath
K, Roussef R, Mamoun R, Portetelle D, Burny A, Adam E, Lefebvre L,
Twizere JC, Heremans H, Kettmann R: Phosphorylation of bovine
leukemia virus Tax protein is required for in vitro transfor-
mation but not for transactivation.  Oncogene 1998,
16:2165-2176.
200. Twizere JC, Kerkhofs P, Burny A, Portetelle D, Kettmann R, Willems
L: Discordance between bovine leukemia virus tax immortal-
ization in vitro and oncogenicity in vivo.  J Virol 2000,
74:9895-9902.
201. Szynal M, Cleuter Y, Beskorwayne T, Bagnis C, Van Lint C, Kerkhofs
P, Burny A, Martiat P, Griebel P, Van den BA: Disruption of B-cell
homeostatic control mediated by the BLV-Tax oncoprotein:
association with the upregulation of Bcl-2 and signaling
through NF-kappaB.  Oncogene 2003, 22:4531-4542.
202. Klener P, Szynal M, Cleuter Y, Merimi M, Duvillier H, Lallemand F, Bag-
nis C, Griebel P, Sotiriou C, Burny A, Martiat P, Van den BA: Insights
into gene expression changes impacting B-cell transforma-
tion: cross-species microarray analysis of bovine leukemia
virus tax-responsive genes in ovine B cells.  J Virol 2006,
80:1922-1938.
203. Philpott SM, Buehring GC: Defective DNA repair in cells with
human T-cell leukemia/bovine leukemia viruses: role of tax
gene.  J Natl Cancer Inst 1999, 91:933-942.
204. Twizere JC, Lefebvre L, Collete D, Debacq C, Urbain P, Heremans H,
Jauniaux JC, Burny A, Willems L, Kettmann R: The homeobox pro-
tein MSX2 interacts with tax oncoproteins and represses
their transactivation activity.  J Biol Chem 2005, 280:29804-29811.
205. Twizere JC, Springael JY, Boxus M, Burny A, Dequiedt F, Dewulf JF,
Duchateau J, Portetelle D, Urbain P, Van Lint C, Green PL, Mahieux R,
Parmentier M, Willems L, Kettmann R: Human T-cell leukemia
virus type-1 Tax oncoprotein regulates G protein signaling.
Blood 2006.
206. Buehring GC, Kramme PM, Schultz RD: Evidence for bovine leuke-
mia virus in mammary epithelial cells of infected cows.  Lab
Invest 1994, 71:359-365.
207. Domenech A, Goyache J, Llames L, Jesus PM, Suarez G, Gomez-Lucia
E: In vitro infection of cells of the monocytic/macrophage lin-
eage with bovine leukaemia virus.  J Gen Virol 2000, 81:109-118.
208. Fulton BE Jr., Portella M, Radke K: Dissemination of bovine leuke-
mia virus-infected cells from a newly infected sheep lymph
node.  J Virol 2006, 80:7873-7884.
209. Heeney JL, Valli PJ, Jacobs RM, Valli VE: Evidence for bovine leuke-
mia virus infection of peripheral blood monocytes and limited
antigen expression in bovine lymphoid tissue.  Lab Invest 1992,
66:608-617.
210. Rovnak J, Casey JW, Boyd AL, Gonda MA, Cockerell GL: Isolation of
bovine leukemia virus infected endothelial cells from cattle
with persistent lymphocytosis.  Lab Invest 1991, 65:192-202.
211. Stott ML, Thurmond MC, Dunn SJ, Osburn BI, Stott JL: Integrated
bovine leukosis proviral DNA in T helper and T cytotoxic/sup-
pressor lymphocytes.  J Gen Virol 1991, 72 ( Pt 2):307-315.
212. Altreuther G, Llames L, Neuenschwander S, Langhans W, Werling D:
Morphologic and functional changes in bovine monocytes
infected in vitro with the bovine leukaemia virus.  Scand J Immu-
nol 2001, 54:459-469.
213. Wu D, Murakami K, Morooka A, Jin H, Inoshima Y, Sentsui H: In vivo
transcription of bovine leukemia virus and bovine immunode-
ficiency-like virus.  Virus Res 2003, 97:81-87.
214. Aida Y, Miyasaka M, Okada K, Onuma M, Kogure S, Suzuki M, Minop-
rio P, Levy D, Ikawa Y: Further phenotypic characterization of
target cells for bovine leukemia virus experimental infection
in sheep.  Am J Vet Res 1989, 50:1946-1951.
215. Aida Y, Okada K, Amanuma H: Phenotype and ontogeny of cells
carrying a tumor-associated antigen that is expressed onRetrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 29 of 32
(page number not for citation purposes)
bovine leukemia virus-induced lymphosarcoma.  Cancer Res
1993, 53:429-437.
216. Mirsky ML, Da Y, Lewin HA: Detection of bovine leukemia virus
proviral DNA in individual cells.  PCR Methods Appl 1993,
2:333-340.
217. Mirsky ML, Olmstead CA, Da Y, Lewin HA: The prevalence of pro-
viral bovine leukemia virus in peripheral blood mononuclear
cells at two subclinical stages of infection.  J Virol 1996,
70:2178-2183.
218. Vernau W, Jacobs RM, Valli VE, Heeney JL: The immunophenotypic
characterization of bovine lymphomas.  Vet Pathol 1997,
34:222-225.
219. Wu D, Takahashi K, Murakami K, Tani K, Koguchi A, Asahina M,
Goryo M, Aida Y, Okada K: B-1a, B-1b and conventional B cell
lymphoma from enzootic bovine leukosis.  Vet Immunol Immun-
opathol 1996, 55:63-72.
220. Saini SS, Allore B, Jacobs RM, Kaushik A: Exceptionally long
CDR3H region with multiple cysteine residues in functional
bovine IgM antibodies.  Eur J Immunol 1999, 29:2420-2426.
221. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E,
Petlickovski A, Efremov DG, Croce CM, Chiorazzi N: B cell recep-
tors in TCL1 transgenic mice resemble those of aggressive,
treatment-resistant human chronic lymphocytic leukemia.
Proc Natl Acad Sci U S A 2006, 103:11713-11718.
222. Depelchin A, Letesson JJ, Lostrie-Trussart N, Mammerickx M, Porte-
telle D, Burny A: Bovine leukemia virus (BLV)-infected B-cells
express a marker similar to the CD5 T cell marker.  Immunol
Lett 1989, 20:69-76.
223. Letesson JJ, Mager A, Mammerickx M, Burny A, Depelchin A: B cells
from bovine leukemia virus- (BLV) infected sheep with hema-
tological disorders express the CD5 T cell marker.  Leukemia
1990, 4:377-379.
224. Matheise JP, Delcommenne M, Mager A, Didembourg CH, Letesson JJ:
CD5+ B cells from bovine leukemia virus infected cows are
activated cycling cells responsive to interleukin 2.  Leukemia
1992, 6:304-309.
225. Meirom R, Moss S, Brenner J: Bovine leukemia virus-gp51 antigen
expression is associated with CD5 and IgM markers on
infected lymphocytes.  Vet Immunol Immunopathol 1997,
59:113-119.
226. Cantor GH, Palmer GH: Antisense oligonucleotide inhibition of
bovine leukemia virus tax expression in a cell-free system.
Antisense Res Dev 1992, 2:147-152.
227. Hamilton VT, Stone DM, Cantor GH: Translocation of the B cell
receptor to lipid rafts is inhibited in B cells from BLV-
infected, persistent lymphocytosis cattle.  Virology 2003,
315:135-147.
228. Chevallier N, Berthelemy M, Le Rhun D, Laine V, Levy D, Schwartz-
Cornil I: Bovine leukemia virus-induced lymphocytosis and
increased cell survival mainly involve the CD11b+ B-lym-
phocyte subset in sheep.  J Virol 1998, 72:4413-4420.
229. Murakami K, Okada K, Ikawa Y, Aida Y: Bovine leukemia virus
induces CD5- B cell lymphoma in sheep despite temporarily
increasing CD5+ B cells in asymptomatic stage.  Virology 1994,
202:458-465.
230. Takahashi M, Tajima S, Takeshima SN, Konnai S, Yin SA, Okada K,
Davis WC, Aida Y: Ex vivo survival of peripheral blood mononu-
clear cells in sheep induced by bovine leukemia virus (BLV)
mainly occurs in CD5- B cells that express BLV.  Microbes Infect
2004, 6:584-595.
231. Aida Y, Okada K, Ohtsuka M, Amanuma H: Tumor-associated M(r)
34,000 and M(r) 32,000 membrane glycoproteins that are ser-
ine phosphorylated specifically in bovine leukemia virus-
induced lymphosarcoma cells.  Cancer Res 1992, 52:6463-6470.
232. Aida Y, Amanuma H, Okada K: Identification of tumor-associated
antigen that is expressed on bovine leukemia virus-induced
lymphosarcoma cells and expression of its human homologue
in human T-cell lymphotrophic virus I-infected cell lines.
Leukemia 1994, 8 Suppl 1:S231-S234.
233. Aida Y, Nishino Y, Amanuma H, Murakami K, Okada K, Ikawa Y: The
role of tumor-associated antigen in bovine leukemia virus-
induced lymphosarcoma.  Leukemia 1997, 11 Suppl 3:216-218.
234. Stone DM, Hof AJ, Davis WC: Up-regulation of IL-2 receptor
alpha and MHC class II expression on lymphocyte subpopula-
tions from bovine leukemia virus infected lymphocytotic
cows.  Vet Immunol Immunopathol 1995, 48:65-76.
235. Hanon E, Stinchcombe JC, Saito M, Asquith BE, Taylor GP, Tanaka Y,
Weber JN, Griffiths GM, Bangham CR: Fratricide among CD8(+)
T lymphocytes naturally infected with human T cell lympho-
tropic virus type I.  Immunity 2000, 13:657-664.
236. Nagai M, Brennan MB, Sakai JA, Mora CA, Jacobson S: CD8(+) T cells
are an in vivo reservoir for human T-cell lymphotropic virus
type I.  Blood 2001, 98:1858-1861.
237. Willems L, Portetelle D, Kerkhofs P, Chen G, Burny A, Mammerickx
M, Kettmann R: In vivo transfection of bovine leukemia provirus
into sheep.  Virology 1992, 189:775-777.
238. Rovnak J, Boyd AL, Casey JW, Gonda MA, Jensen WA, Cockerell GL:
Pathogenicity of molecularly cloned bovine leukemia virus.  J
Virol 1993, 67:7096-7105.
239. Bartoe JT, Albrecht B, Collins ND, Robek MD, Ratner L, Green PL,
Lairmore MD: Functional role of pX open reading frame II of
human T-lymphotropic virus type 1 in maintenance of viral
loads in vivo.  J Virol 2000, 74:1094-1100.
240. Collins ND, Newbound GC, Albrecht B, Beard JL, Ratner L, Lairmore
MD: Selective ablation of human T-cell lymphotropic virus
type 1 p12I reduces viral infectivity in vivo.  Blood 1998,
91:4701-4707.
241. Silverman LR, Phipps AJ, Montgomery A, Ratner L, Lairmore MD:
Human T-cell lymphotropic virus type 1 open reading frame
II-encoded p30II is required for in vivo replication: evidence
of in vivo reversion.  J Virol 2004, 78:3837-3845.
242. Van den BA, Cleuter Y, Beskorwayne T, Kerkhofs P, Szynal M, Bagnis
C, Burny A, Griebel P: CD154 costimulated ovine primary B
cells, a cell culture system that supports productive infection
by bovine leukemia virus.  J Virol 2001, 75:1095-1103.
243. Kettmann R, Bruck C, Mammerickx M, Burny A: BLV proviral DNA
in the genome of the target lymphocyte.  Arch Geschwulstforsch
1980, 50:735-742.
244. Debacq C, Sanchez Alcaraz MT, Mortreux F, Kerkhofs P, Kettmann R,
Willems L: Reduced proviral loads during primo-infection of
sheep by Bovine Leukemia virus attenuated mutants.  Retrovi-
rology 2004, 1:31.
245. Moules V, Pomier C, Sibon D, Gabet AS, Reichert N, Kerkhofs P, Wil-
lems L, Mortreux F, Wattel E: Fate of premalignant clones during
the asymptomatic phase preceding lymphoid malignancy.
Cancer Research 2005, 65:1234-1243.
246. Kettmann R, Deschamps J, Cleuter Y, Couez D, Burny A, Marbaix G:
Leukemogenesis by bovine leukemia virus: proviral DNA
integration and lack of RNA expression of viral long terminal
repeat and 3' proximate cellular sequences.  Proc Natl Acad Sci U
S A 1982, 79:2465-2469.
247. Deschamps J, Kettmann R, Burny A: Experiments with cloned
complete tumor-derived bovine leukemia virus information
prove that the virus is totally exogenous to its target animal
species.  J Virol 1981, 40:605-609.
248. Ogawa Y, Sagata N, Tsuzuku-Kawamura J, Onuma M, Izawa H, Ikawa
Y:  No involvement of bovine leukemia virus in sporadic
bovine lymphosarcoma.  Microbiol Immunol 1986, 30:697-701.
249. Gregoire D, Couez D, Deschamps J, Heuertz S, Hors-Cayla MC,
Szpirer J, Szpirer C, Burny A, Huez G, Kettmann R: Different bovine
leukemia virus-induced tumors harbor the provirus in differ-
ent chromosomes.  J Virol 1984, 50:275-279.
250. Kettmann R, Deschamps J, Couez D, Claustriaux JJ, Palm R, Burny A:
Chromosome integration domain for bovine leukemia provi-
rus in tumors.  J Virol 1983, 47:146-150.
251. Kettmann R, Marbaix G, Cleuter Y, Portetelle D, Mammerickx M,
Burny A: Genomic integration of bovine leukemia provirus and
lack of viral RNA expression in the target cells of cattle with
different responses to BLV infection.  Leuk Res 1980, 4:509-519.
252. Kettmann R, Cleuter Y, Gregoire D, Burny A: Role of the 3' long
open reading frame region of bovine leukemia virus in the
maintenance of cell transformation.  J Virol 1985, 54:899-901.
253. Gaynor EM, Mirsky ML, Lewin HA: Use of flow cytometry and RT-
PCR for detecting gene expression by single cells.  Biotechniques
1996, 21:286-291.
254. Jensen WA, Rovnak J, Cockerell GL: In vivo transcription of the
bovine leukemia virus tax/rex region in normal and neoplastic
lymphocytes of cattle and sheep.  J Virol 1991, 65:2484-2490.
255. Lagarias DM, Radke K: Transcriptional activation of bovine
leukemia virus in blood cells from experimentally infected,
asymptomatic sheep with latent infections.  J Virol 1989,
63:2099-2107.
256. Radke K, Sigala TJ, Grossman D: Transcription of bovine leukemia
virus in peripheral blood cells obtained during early infection
in vivo.  Microb Pathog 1992, 12:319-331.
257. Gupta P, Ferrer JF: Expression of bovine leukemia virus genome
is blocked by a nonimmunoglobulin protein in plasma from
infected cattle.  Science 1982, 215:405-407.
258. Gupta P, Kashmiri SV, Ferrer JF: Transcriptional control of the
bovine leukemia virus genome: role and characterization of a
non-immunoglobulin plasma protein from bovine leukemia
virus-infected cattle.  J Virol 1984, 50:267-270.Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 30 of 32
(page number not for citation purposes)
259. van den Heuvel MJ, Jefferson BJ, Jacobs RM: Isolation of a bovine
plasma fibronectin-containing complex which inhibits the
expression of bovine leukemia virus p24.  J Virol 2005,
79:8164-8170.
260. Tsukiyama K, Onuma M, Izawa H: Effect of platelet-derived factor
on expression of bovine leukemia virus genome.  Arch Virol
1987, 96:89-96.
261. Tajima S, Aida Y: Induction of expression of bovine leukemia
virus (BLV) in blood taken from BLV-infected cows without
removal of plasma.  Microbes Infect 2005, 7:1211-1216.
262. Driscoll DM, Baumgartener LE, Olson C: Concanavalin A and the
production of bovine leukemia virus antigen in short-term
lymphocyte cultures.  J Natl Cancer Inst 1977, 58:1513-1514.
263. Trueblood ES, Brown WC, Palmer GH, Davis WC, Stone DM, McEl-
wain TF: B-lymphocyte proliferation during bovine leukemia
virus-induced persistent lymphocytosis is enhanced by T-lym-
phocyte-derived interleukin-2.  J Virol 1998, 72:3169-3177.
264. Stock ND, Ferrer JF: Replicating C-type virus in phytohemagglu-
tinin-treated buffy-coat cultures of bovine origin.  J Natl Cancer
Inst 1972, 48:985-996.
265. Kidd LC, Radke K: Lymphocyte activators elicit bovine leuke-
mia virus expression differently as asymptomatic infection
progresses.  Virology 1996, 217:167-177.
266. Jensen WA, Wicks-Beard BJ, Cockerell GL: Inhibition of protein
kinase C results in decreased expression of bovine leukemia
virus.  J Virol 1992, 66:4427-4433.
267. Kerkhofs P, Adam E, Droogmans L, Portetelle D, Mammerickx M,
Burny A, Kettmann R, Willems L: Cellular pathways involved in
the ex vivo expression of bovine leukemia virus.  J Virol 1996,
70:2170-2177.
268. Cornil I, Delon P, Parodi AL, Levy D: T-B cell cooperation for
bovine leukemia virus expression in ovine lymphocytes.  Leuke-
mia 1988, 2:313-317.
269. Djilali S, Parodi AL, Levy D: Bovine leukemia virus replicates in
sheep B lymphocytes under a T cell released factor.  Eur J Can-
cer Clin Oncol 1987, 23:81-85.
270. Pyeon D, O'Reilly KL, Splitter GA: Increased interleukin-10
mRNA expression in tumor-bearing or persistently lym-
phocytotic animals infected with bovine leukemia virus.  J Virol
1996, 70:5706-5710.
271. Yakobson B, Brenner J, Ungar-Waron H, Trainin Z: Short-termed
expression of interleukin-12 during experimental BLV infec-
tion may direct disease progression to persistent lymphocy-
tosis.  Vet Immunol Immunopathol 1998, 64:207-218.
272. Pyeon D, Splitter GA: Regulation of bovine leukemia virus tax
and pol mRNA levels by interleukin-2 and -10.  J Virol 1999,
73:8427-8434.
273. Pyeon D, Diaz FJ, Splitter GA: Prostaglandin E(2) increases
bovine leukemia virus tax and pol mRNA levels via cyclooxy-
genase 2: regulation by interleukin-2, interleukin-10, and
bovine leukemia virus.  J Virol 2000, 74:5740-5745.
274. Amills M, Ramiya V, Norimine J, Olmstead CA, Lewin HA: Reduced
IL-2 and IL-4 mRNA expression in CD4+ T cells from bovine
leukemia virus-infected cows with persistent lymphocytosis.
Virology 2002, 304:1-9.
275. Isaacson JA, Flaming KP, Roth JA: Increased MHC class II and
CD25 expression on lymphocytes in the absence of persistent
lymphocytosis in cattle experimentally infected with bovine
leukemia virus.  Vet Immunol Immunopathol 1998, 64:235-248.
276. Sordillo LM, Hicks CR, Pighetti GM: Altered interleukin-2 produc-
tion by lymphocyte populations from bovine leukemia virus-
infected cattle.  Proc Soc Exp Biol Med 1994, 207:268-273.
277. Stone DM, McElwain TF, Davis WC: Enhanced B-lymphocyte
expression of IL-2R alpha associated with T lymphocytosis in
BLV-infected persistently lymphocytotic cows.  Leukemia 1994,
8:1057-1061.
278. Keefe RG, Ferrick DA, Stott JL: Cytokine transcription in lymph
nodes of cattle in different stages of bovine leukemia virus
infection.  Vet Immunol Immunopathol 1997, 59:271-283.
279. Amills M, Norimine J, Olmstead CA, Lewin HA: Cytokine mRNA
expression in B cells from bovine leukemia virus-infected cat-
tle with persistent lymphocytosis.  Cytokine 2004, 28:25-28.
280. Meirom R, Moss S, Brenner J, Heller D, Trainin Z: Levels and role of
cytokines in bovine leukemia virus (BLV) infection.  Leukemia
1997, 11 Suppl 3:219-220.
281. Keefe RG, Choi Y, Ferrick DA, Stott JL: Bovine cytokine expres-
sion during different phases of bovine leukemia virus infec-
tion.  Vet Immunol Immunopathol 1997, 56:39-51.
282. Konnai S, Usui T, Ohashi K, Onuma M: The rapid quantitative
analysis of bovine cytokine genes by real-time RT-PCR.  Vet
Microbiol 2003, 94:283-294.
283. Muller C, Coffey TJ, Koss M, Teifke JP, Langhans W, Werling D: Lack
of TNF alpha supports persistence of a plasmid encoding the
bovine leukaemia virus in TNF(-/-) mice.  Vet Immunol Immun-
opathol 2003, 92:15-22.
284. Kabeya H, Ohashi K, Onuma M: Host immune responses in the
course of bovine leukemia virus infection.  J Vet Med Sci 2001,
63:703-708.
285. Usui T, Konnai S, Ohashi K, Onuma M: Expression of tumor necro-
sis factor-alpha in IgM+ B-cells from bovine leukemia virus-
infected lymphocytotic sheep.  Vet Immunol Immunopathol 2006,
112:296-301.
286. Kabeya H, Ohashi K, Oyunbileg N, Nagaoka Y, Aida Y, Sugimoto C,
Yokomizo Y, Onuma M: Up-regulation of tumor necrosis factor
alpha mRNA is associated with bovine-leukemia virus (BLV)
elimination in the early phase of infection.  Vet Immunol Immun-
opathol 1999, 68:255-265.
287. Konnai S, Usui T, Ikeda M, Kohara J, Hirata T, Okada K, Ohashi K,
Onuma M: Tumor necrosis factor-alpha up-regulation in spon-
taneously proliferating cells derived from bovine leukemia
virus-infected cattle.  Arch Virol 2006, 151:347-360.
288. Konnai S, Usui T, Ikeda M, Kohara J, Hirata T, Okada K, Ohashi K,
Onuma M: Imbalance of tumor necrosis factor receptors dur-
ing progression in bovine leukemia virus infection.  Virology
2005, 339:239-248.
289. Sentsui H, Murakami K, Inoshima Y, Yokoyama T, Inumaru S: Anti-
viral effect of recombinant bovine interferon gamma on
bovine leukaemia virus.  Cytokine 2001, 16:227-231.
290. Usui T, Konnai S, Ohashi K, Onuma M: Interferon-gamma expres-
sion associated with suppression of bovine leukemia virus at
the early phase of infection in sheep.  Vet Immunol Immunopathol
2006.
291. Murakami K, Sentsui H, Inoshima Y, Inumaru S: Increase in gam-
madelta T cells in the blood of cattle persistently infected
with bovine leukemia virus following administration of
recombinant bovine IFN-gamma.  Vet Immunol Immunopathol
2004, 101:61-71.
292. Yakobson B, Brenner J, Ungar-Waron H, Trainin Z: Cellular
immune response cytokine expression during the initial stage
of bovine leukemia virus (BLV) infection determines the dis-
ease progression to persistent lymphocytosis.  Comp Immunol
Microbiol Infect Dis 2000, 23:197-208.
293. Klintevall K, Fuxler L, Fossum C: Bovine leukemia virus: early
reflections in blood after an experimental infection of calves.
Comp Immunol Microbiol Infect Dis 1997, 20:119-130.
294. Kohara J, Yokomizo Y: In Vitro and In Vivo Effects of Recom-
binant Bovine Interferon-tau on Bovine Leukemia Virus.  J Vet
Med Sci 2007, 69:15-19.
295. Dequiedt F, Kettmann R, Burny A, Willems L: Nucleotide sequence
of the ovine P53 tumor-suppressor cDNA and its genomic
organization.  DNA Seq 1995, 5:255-259.
296. Ishiguro N, Furuoka H, Matsui T, Horiuchi M, Shinagawa M, Asahina M,
Okada K: p53 mutation as a potential cellular factor for tumor
development in enzootic bovine leukosis.  Vet Immunol Immun-
opathol 1997, 55:351-358.
297. Zhuang W, Tajima S, Okada K, Ikawa Y, Aida Y: Point mutation of
p53 tumor suppressor gene in bovine leukemia virus-induced
lymphosarcoma.  Leukemia 1997, 11 Suppl 3:344-346.
298. Tajima S, Zhuang WZ, Kato MV, Okada K, Ikawa Y, Aida Y: Function
and Conformation of Wild-Type p53 Protein Are Influenced
by Mutations in Bovine Leukemia Virus-Induced B-Cell Lym-
phosarcoma.  Virology 1998, 243:235-246.
299. Reyes RA, Cockerell GL: Increased ratio of bcl-2/bax expression
is associated with bovine leukemia virus-induced leukemo-
genesis in cattle.  Virology 1998, 242:184-192.
300. Dequiedt F, Kettmann R, Burny A, Willems L: Mutations in the p53
tumor-suppressor gene are frequently associated with bovine
leukemia virus-induced leukemogenesis in cattle but not in
sheep.  Virology 1995, 209:676-683.
301. Schnurr MW, Carter RF, Dube ID, Valli VE, Jacobs RM: Nonrandom
chromosomal abnormalities in bovine lymphoma.  Leuk Res
1994, 18:91-99.
302. Lewin HA, Russell GC, Glass EJ: Comparative organization and
function of the major histocompatibility complex of domesti-
cated cattle.  Immunol Rev 1999, 167:145-158.
303. Lewin HA, Bernoco D: Evidence for BoLA-linked resistance and
susceptibility to subclinical progression of bovine leukaemia
virus infection.  Anim Genet 1986, 17:197-207.
304. Lewin HA, Wu MC, Stewart JA, Nolan TJ: Association between
BoLA and subclinical bovine leukemia virus infection in a
herd of Holstein-Friesian cows.  Immunogenetics 1988,
27:338-344.Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 31 of 32
(page number not for citation purposes)
305. Xu A, van Eijk MJ, Park C, Lewin HA: Polymorphism in BoLA-
DRB3 exon 2 correlates with resistance to persistent lym-
phocytosis caused by bovine leukemia virus.  J Immunol 1993,
151:6977-6985.
306. Zanotti M, Poli G, Ponti W, Polli M, Rocchi M, Bolzani E, Longeri M,
Russo S, Lewin HA, van Eijk MJ: Association of BoLA class II hap-
lotypes with subclinical progression of bovine leukaemia virus
infection in Holstein-Friesian cattle.  Anim Genet 1996,
27:337-341.
307. Mirsky ML, Olmstead C, Da Y, Lewin HA: Reduced bovine leukae-
mia virus proviral load in genetically resistant cattle.  Anim
Genet 1998, 29:245-252.
308. Konnai S, Usui T, Ikeda M, Kohara J, Hirata TI, Okada K, Ohashi K,
Onuma M: Tumor necrosis factor-alpha genetic polymorphism
may contribute to progression of bovine leukemia virus-infec-
tion.  Microbes Infect 2006.
309. Nagaoka Y, Kabeya H, Onuma M, Kasai N, Okada K, Aida Y: Ovine
MHC class II DRB1 alleles associated with resistance or sus-
ceptibility to development of bovine leukemia virus-induced
ovine lymphoma.  Cancer Res 1999, 59:975-981.
310. Konnai S, Takeshima SN, Tajima S, Yin SA, Okada K, Onuma M, Aida
Y:  The influence of ovine MHC class II DRB1 alleles on
immune response in bovine leukemia virus infection.  Microbiol
Immunol 2003, 47:223-232.
311. Portetelle D, Mammerickx M, Burny A: Use of two monoclonal
antibodies in an ELISA test for the detection of antibodies to
bovine leukaemia virus envelope protein gp51.  J Virol Methods
1989, 23:211-222.
312. Radke K, Grossman D, Kidd LC: Humoral immune response of
experimentally infected sheep defines two early periods of
bovine leukemia virus replication.  Microb Pathog 1990,
9:159-171.
313. Portetelle D, Bruck C, Burny A, Dekegel D, Mammerickx M, Urbain J:
Detection of complement-dependent lytic antibodies in sera
from bovine leukemia virus-infected animals.  Ann Rech Vet
1978, 9:667-674.
314. Nagy DW, Tyler JW, Stoker A, Kleiboeker SB: Association
between the strength of serologic recognition of bovine leu-
kosis virus and lymphocyte count in bovine leukosis virus-
infected cows.  J Am Vet Med Assoc 2002, 220:1681-1684.
315. Lundberg P, Splitter GA: gammadelta(+) T-Lp6phocyte cytotox-
icity against envelope-expressing target cells is unique to the
alymphocytic state of bovine leukemia virus infection in the
natural host.  J Virol 2000, 74:8299-8306.
316. Kabeya H, Ohashi K, Sugimoto C, Onuma M: Characterization of
immune responses caused by bovine leukemia virus envelope
peptides in sheep.  J Vet Med Sci 1999, 61:475-480.
317. Stone DM, Norton LK, Chambers JC, Meek WJ: CD4 T lymphocyte
activation in BLV-induced persistent B lymphocytosis in cat-
tle.  Clin Immunol 2000, 96:280-288.
318. Oldstone MBA: Viral persistence: Parameters, mechanisms
and future predictions.  Virology 2006, 344:111-118.
319. Brenner J, Van Haam M, Savir D, Trainin Z: The implication of BLV
infection in the productivity, reproductive capacity and sur-
vival rate of a dairy cow.  Vet Immunol Immunopathol 1989,
22:299-305.
320. Wattel E, Cavrois M, Gessain A, WainHobson S: Clonal expansion
of infected cells: A way of life for HTLV-I.  Journal of Acquired
Immune Deficiency Syndromes and Human Retrovirology 1996,
13:S92-S99.
321. Dequiedt F, Hanon E, Kerkhofs P, Pastoret PP, Portetelle D, Burny A,
Kettmann R, Willems L: Both wild-type and strongly attenuated
bovine leukemia viruses protect peripheral blood mononu-
clear cells from apoptosis.  J Virol 1997, 71:630-639.
322. Schwartz-Cornil I, Chevallier N, Belloc C, Le Rhun D, Laine V, Ber-
thelemy M, Mateo A, Levy D: Bovine leukaemia virus-induced
lymphocytosis in sheep is associated with reduction of spon-
taneous B cell apoptosis.  J Gen Virol 1997, 78 ( Pt 1):153-162.
323. Alcaraz TS, Kerkhofs P, Reichert M, Kettmann R, Willems L: Involve-
ment of glutathione as a mechanism of indirect protection
against spontaneous ex vivo apoptosis associated with bovine
leukemia virus.  Journal of Virology 2004, 78:6180-6189.
324. Debacq C, Asquith B, Reichert M, Burny A, Kettmann R, Willems L:
Reduced cell turnover in bovine leukemia virus-infected, per-
sistently lymphocytotic cattle.  J Virol 2003, 77:13073-13083.
325. Dequiedt F, Cantor GH, Hamilton VT, Pritchard SM, Davis WC,
Kerkhofs P, Burny A, Kettmann R, Willems L: Bovine leukemia
virus-induced persistent lymphocytosis in cattle does not cor-
relate with increased ex vivo survival of B lymphocytes.  J Virol
1999, 73:1127-1137.
326. Gupta P, Kashmiri SV, Erisman MD, Rothberg PG, Astrin SM, Ferrer JF:
Enhanced expression of the c-myc gene in bovine leukemia
virus-induced bovine tumors.  Cancer Res 1986, 46:6295-6298.
327. Hailata N, Johnson R, al Bagdadi F, Hanash S: Proliferating cell
nuclear antigen expression in sheep infected with bovine
leukemia virus.  Vet Immunol Immunopathol 1995, 44:211-222.
328. Stone DM, Norton LK, Magnuson NS, Davis WC: Elevated pim-1
and c-myc proto-oncogene induction in B lymphocytes from
BLV-infected cows with persistent B lymphocytosis.  Leukemia
1996, 10:1629-1638.
329. Debacq C, Asquith B, Kerkhofs P, Portetelle D, Burny A, Kettmann R,
Willems L: Increased cell proliferation, but not reduced cell
death, induces lymphocytosis in bovine leukemia virus-
infected sheep.  Proc Natl Acad Sci U S A 2002, 99:10048-10053.
330. Jacobs A, Clark RE: Pathogenesis and Clinical Variations in the
Myelodysplastic Syndromes.  Clinics in Haematology 1986,
15:925-951.
331. Ristevski B, Young AJ, Dudler L, Cahill RNP, Kimpton W, Washington
E, Hay JB: Tracking dendritic cells: use of an in situ method to
label all blood leukocytes.  International Immunology 2003,
15:159-165.
332. Hay JB, Andrade WN: Lymphocyte recirculation, exercise, and
immune responses.  Can J Physiol Pharmacol 1998, 76:490-496.
333. Hein WR, Griebel PJ: A road less travelled: large animal models
in immunological research.  Nat Rev Immunol 2003, 3:79-84.
334. Young AJ, Hay JB, Mackay CR: Lymphocyte recirculation and life
span in vivo.  Curr Top Microbiol Immunol 1993, 184:161-173.
335. Debacq C, Gillet N, Asquith B, Sanchez-Alcaraz MT, Florins A, Boxus
M, Schwartz-Cornil I, Bonneau M, Jean G, Kerkhofs P, Hay J, Thewis A,
Kettmann R, Willems L: Peripheral blood B-cell death compen-
sates for excessive proliferation in lymphoid tissues and main-
tains homeostasis in bovine leukemia virus-infected sheep.  J
Virol 2006, 80:9710-9719.
336. Asquith B, Debacq C, Florins A, Gillet N, Sanchez Alcaraz MT, Mosley
A, Willems L: Quantifying lymphocyte kinetics in vivo using
CFSE.  Proceedings of the Royal Society of London 2006, in press:.
337. Florins A, Gillet N, Asquith B, Debacq C, Jean G, Schwartz-Cornil I,
Bonneau M, Burny A, Reichert M, Kettmann R, Willems L: Spleen-
Dependent Turnover of CD11b Peripheral Blood B Lym-
phocytes in Bovine Leukemia Virus-Infected Sheep.  J Virol
2006, 80:11998-12008.
338. Achachi A, Florins A, Gillet N, Debacq C, Urbain P, Foutsop GM, Van-
dermeers F, Jasik A, Reichert M, Kerkhofs P, Lagneaux L, Burny A,
Kettmann R, Willems L: Valproate activates bovine leukemia
virus gene expression, triggers apoptosis, and induces leuke-
mia/lymphoma regression in vivo.  Proc Natl Acad Sci U S A 2005,
102:10309-10314.
339. Kamoi K, Yamamoto K, Misawa A, Miyake A, Ishida T, Tanaka Y,
Mochizuki M, Watanabe T: SUV39H1 interacts with HTLV-1 Tax
and abrogates Tax transactivation of HTLV-1 LTR.  Retrovirol-
ogy 2006, 3:5.
340. Hivin P, Basbous J, Raymond F, Henaff D, Arpin-Andre C, Robert-Heb-
mann V, Barbeau B, Mesnard JM: The HBZ-SP1 isoform of human
T-cell leukemia virus type I represses JunB activity by seques-
tration into nuclear bodies.  Retrovirology 2007, 4:14.
341. Satou Y, Yasunaga J, Yoshida M, Matsuoka M: HTLV-I basic leucine
zipper factor gene mRNA supports proliferation of adult T
cell leukemia cells.  Proc Natl Acad Sci U S A 2006, 103:720-725.
342. Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M: Induction of inter-
leukin 2 receptor gene expression by p40x encoded by human
T-cell leukemia virus type 1.  EMBO J 1986, 5:2883-2888.
343. Asquith B, Mosley AJ, Heaps A, Tanaka Y, Taylor GP, McLean AR,
Bangham CR: Quantification of the virus-host interaction in
human T lymphotropic virus I infection.  Retrovirology 2005, 2:75.
344. Lagarias DM, Radke K: Transient increases of blood mononu-
clear cells that could express bovine leukemia virus early
after experimental infection of sheep.  Microb Pathog 1990,
9:147-158.
345. Yoo C, Jones P: Epigenetic therapy of cancer: past, present and
future.  Nature reviews 2006, 5:37-50.
346. Blaheta RA, Nau H, Michaelis M, Cinatl J: Valproate and valproate-
analogues: Potent tools to fight against cancer.  Current Medici-
nal Chemistry 2002, 9:1417-1433.
347. Drummond DC, Noble CO, Kirpotin DB, Guo ZX, Scott GK, Benz
CC: Clinical development of histone deacetylase inhibitors as
anticancer agents.  Annual Review of Pharmacology and Toxicology
2005, 45:495-528.
348. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A,
Altucci L, Nervi C, Minucci S, Pelicci PG: Inhibitors of histone
deacetylases induce tumor-selective apoptosis through acti-
vation of the death receptor pathway.  Nature Medicine 2005,
11:71-76.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2007, 4:18 http://www.retrovirology.com/content/4/1/18
Page 32 of 32
(page number not for citation purposes)
349. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo
P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera
AR, Gronemeyer H, Altucci L: Tumor-selective action of HDAC
inhibitors involves TRAIL induction in acute myeloid leuke-
mia cells.  Nature Medicine 2005, 11:77-84.
350. Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I,
Kubota H, Izumo S, Arimura K, Osame M: Therapeutic trials in 200
patients with HTLV-I-associated myelopathy/tropical spastic
paraparesis.  Journal of Neurovirology 1996, 2:345-355.
351. Oh U, Yamano Y, Mora CA, Ohayon J, Bagnato F, Butman JA, Dambro-
sia J, Leist TP, McFarland H, Jacobson S: Interferon-beta 1a therapy
in human T-lymphotropic virus type I-associated neurologic
disease.  Annals of Neurology 2005, 57:526-534.
352. Saito M, Nakagawa M, Kaseda S, Matsuzaki T, Jonosono M, Eiraku N,
Kubota R, Takenouchi N, Nagai M, Furukawa Y, Usuku K, Izumo S,
Osame M: Decreased human T lymphotropic virus type I
(HTLV-I) provirus load and alteration in T cell phenotype
after interferon-alpha therapy for HTLV-I-associated mye-
lopathy/tropical spastic paraparesis.  Journal of Infectious Diseases
2004, 189:29-40.
353. Ikegami M, Umehara F, Ikegami N, Maekawa R, Osame M: Selective
matrix metalloproteinase inhibitor, N-biphenyl sulfonyl phe-
nylalanine hydroxamic acid, inhibits the migration of CD4(+)
T lymphocytes in patients with HTLV-I-associated myelopa-
thy.  Journal of Neuroimmunology 2002, 127:134-138.
354. Machuca A, Soriano V: In vivo fluctuation of HTLV-I and HTLV-
II proviral load in patients receiving antiretroviral drugs.  Jour-
nal of Acquired Immune Deficiency Syndromes 2000, 24:189-193.
355. Sheremata WA, Benedict D, Squilacote DC, Sazant A, Defreitas E:
High-Dose Zidovudine Induction in Htlv-I-Associated Mye-
lopathy - Safety and Possible Efficacy.  Neurology 1993,
43:2125-2129.
356. Taylor GP, Hall SE, Navarrete S, Michie CA, Davis R, Witkover AD,
Rossor M, Nowak MA, Rudge P, Matutes E, Bangham CRM, Weber JN:
Effect of lamivudine on human T-cell leukemia virus type 1
(HTLV-1) DNA copy number, T-cell phenotype, and anti-tax
cytotoxic T-cell frequency in patients with HTLV-1-associ-
ated myelopathy.  Journal of Virology 1999, 73:10289-10295.
357. Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose
H, Babiker A, Rudge P, Usuku K, Osame M, Bangham CR, Weber JN:
Zidovudine plus lamivudine in Human T-Lymphotropic Virus
type-I-associated myelopathy: a randomised trial.  Retrovirology
2006, 3:63.
358. Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de The H, El Sabban ME,
Hermine O: New therapeutic approaches for adult T-cell leu-
kaemia.  Lancet Oncol 2004, 5:664-672.